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1. ABSTRACT 
Canine pulmonary eosinophilia (PE) is a lower respiratory disease involving 
the airways and lung parenchyma and causing bronchial and alveolar epithelial cell 
sloughing, resulting in basement membrane exposure. We characterized clinical and 
clinicopathological features and tissue inflammation in 20 PE dogs by assessing 
cellular changes as well as levels of matrix metalloproteinases (MMPs) -2, -8, -9, and -
13 and laminin-5 ?2-chain degradation products in bronchoalveolar lavage fluid 
(BALF). Sixteen healthy dogs were used as controls, providing reference values for 
BALF. The effect of repeated lavage was evaluated by lavaging the control dogs six 
times at 5- to 7-week intervals.
Analysis indicated that repeated BAL was a safe and a reliable procedure,
having an equal impact on PE and healthy dogs’ arterial blood gas values. Laboratory 
processing caused a significant total cell loss in BALF. In blood, eosinophilia was 
detected in 50% of PE dogs, and in their BALF, cell count, the number and percentage
of eosinophils and the numbers of macrophages, lymphocytes, neutrophils, mast cells, 
and epithelial cells were significantly elevated. Bronchointerstitial densities were
detected in PE dogs’ radiographs.
The levels of gelatinolytic MMPs (-2, -9) and collagenolytic MMPs (-8, -13) in 
BALF were higher in PE dogs than in healthy controls. Immunocytochemical methods
showed that BALF macrophages and epithelial cells were the principal sources of 
MMPs -8 and -9; MMP-13 was found mainly in macrophages. A significant positive 
correlation was noted between the percentage of degraded type I collagen and the 
counts of BALF eosinophils, macrophages, lymphocytes, and mast cells.
We observed that inflammation caused epithelial cell sloughing in association
with the degradation of the laminin-5 ?2-chain into small molecular weight fragments.
The subsidence of inflammation after treatment was found to downregulate this
degradation.
Overall, these findings suggest that upregulation of collagenolytic and 
gelatinolytic MMPs eventually contributes to pulmonary tissue destruction in canine
PE. The laminin-5 ?2-chain degradation products may be linked to epithelial cell 
sloughing and basement membrane exposure or healing.
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3. ABBREVIATIONS
A-aDO2 arterio alveolar oxygen gradient
APMA aminophenylmercuric acetate
ARDS adult respiratory distress syndrome
BAL bronchoalveolar lavage
BALF bronchoalveolar lavage fluid
BM basement membrane
CI confidence interval
COPD chronic obstructive pulmonary disease 
ECL enhanced chemiluminescence
ECM extracellular matrix
EDTA ethylenediaminotetra-acetic acid
ELF epithelial lining fluid
HE hematoxylin-eosin
kDa kilodalton
Ln-5 laminin-5
LPS lipopolysaccharide
MMP matrix metalloproteinase
MT-MMP membrane-type matrix metalloproteinase
MW molecular weight
PaCO2 partial pressure of carbon dioxide in arterial blood
PaO2 partial pressure of oxygen in arterial blood 
PBS phosphate-buffered saline
PE pulmonary eosinophilia
PIE pulmonary infiltrates with eosinophilia
PMN polymorphonuclear leukocyte
r  correlation coefficient
SD standard deviation
SDS sodium dodecyl sulfate
TIMP tissue inhibitor of matrix metalloproteinases
TNF? tumor necrosis factor alpha
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4. INTRODUCTION
Canine pulmonary eosinophilia (PE), also known as pulmonary infiltrates with 
eosinophilia (PIE), eosinophilic pneumonia, pulmonary hypersensitivity, and 
eosinophilic bronchopneumopathy is a syndrome characterized by eosinophil 
accumulation in the lung tissue and airways (Gibbs and Anderson 1990, Corcoran et 
al. 1991, Taboada, 1991, Clercx et al. 2000). PE causes variable respiratory signs, 
including cough and dyspnea, as well as such nonrespiratory symptoms as weight loss, 
lethargy, and fever (Hawkins 1998).
Lung inflammation can to some extent be studied by nondirect methods, e.g. 
blood tests and radiographs, but often changes, as in PE, are limited to the lung. In PE 
cases when blood eosinophilia is not present, special sample collection methods, such 
as bronchoalveolar lavage (BAL), are required. BAL enables characterization of the
cellular profile and the inflammatory mediators collected directly from the site of 
inflammation. Bronchoalveolar lavage fluid (BALF) can be collected by 
bronchoscopic or unguided catheter or tube techniques. The technical protocols can 
vary greatly, for example, the recommended amount of lavage fluid or the laboratory 
processes (Saltini et al. 1984, Klech and Pohl 1989, Hawkins et al. 1990). This has led 
to a wide range of reference values, and thus, each laboratory needs to either set its
own reference values or tightly adhere to established protocols. 
Distal lung parenchyma and the bronchial epithelium are targets of 
inflammatory changes in PE. Proteolytic enzymes, including matrix metalloproteinases
(MMPs), are believed to be the key pivotal mediators of structural changes both in 
pathological and physiological conditions because of their broad and efficient capacity
to cleave various extracellular matrix and basement membrane (BM) proteins, 
including collagens, elastin, and proteoglycan, as well as connective tissue and BM 
glycoproteins (Corbel et al. 2002, Atkinson and Senior 2003). In addition, MMPs can 
process growth factors, cytokines, cell adhesion molecules, chemokines, cell adhesion
molecules, cell surface receptors and apoptotic signals to modulate immune responses
(Parks and Shapiro 2001, Visse and Nagase 2003). Certain MMPs may even exert 
anti-inflammatory or defensive characteristics (Owen et al. 2004). In human
pulmonology, the involvement of MMPs has already been studied for a couple of 
decades, but in veterinary medicine this research field is relatively new. In this field,
equine chronic obstructive pulmonary disease (COPD) is probably the best described 
animal disease. However, to our knowledge, no studies on canine pulmonary diseases 
prior to ours have been published. 
Here, pathophysiologic changes in PE dogs, with special reference to MMPs, 
are compared with findings in healthy control dogs.
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5. REVIEW OF THE LITERATURE 
5.1. Anatomy of a healthy canine lung 
The lower respiratory tract includes the trachea (trachea), the main bronchi 
(bronchi principales), and the lungs (pulmo). The right lung (pulmo dexter) is larger 
than the left (pulmo sinister) and divided into four lobes: cranial (lobus cranialis),
medial (lobus medialis), caudal (lobus caudalis), and accessory (lobus accessorius).
The left lung consists of cranial and caudal lobes. The main bronchi divide into lobar
bronchi (bronchi lobares), and thereafter, into segmental bronchi (bronchi
segmentales). Each segmental bronchus and a portion of the lung behind it form an 
independent, coniform bronchopulmonary segment. In dogs, these segments are 
connected to each other, which enables ventilation also during the blockade to smaller
bronchi (collateral ventilation). 
Segmental bronchi divide into subsegmental bronchi (bronchi subsegmentales),
which divide into bronchioles (bronchuli), then into terminal bronchioles (bronchuli
terminales), respiratory bronchioles (bronchioles respiratorii), and finally, into the 
alveolar duct (ductus alveolares), which extends inside the alveolar sacs (sacculi
alveolares) (Nickel et al. 1960).
Alveolar sacs are surrounded by the lung interstitium, which represents an 
anatomic space between the BMs under the alveolar epithelial cells and the capillary
endothelial cells. The boundaries of the interstitium extend to include the perivascular, 
perilymphatic, and peribronchiolar connective tissues, and the alveolar lumen. The
interstitium contains the extracellular matrix, which is made up of macromolecules,
including collagen, proteoglycans, and glycoproteins, as well as the noncollagenous
proteins fibronectin and laminin. Low numbers of interstitial macrophages, fibroblasts, 
and myofibroblasts are also present.
The lung interfaces with the environment across a heterogeneous and
continuous layer of epithelium attached to the BM. Bronchi are lined with ciliated, 
pseudostratified columnar epithelial cells that diminish in height to a simple cuboidal
ciliated and gradually to a nonciliated epithelium layer in more distal airways. 
Numerous cells, including basal, goblet, and Clara cells, are present along the airways. 
Epithelial cells are attached to the thin BM by hemidesmosomes and to basal cells by 
desmosomes. Tissue below the epithelium is histologically divided into different 
layers called the lamina propria, submucosa, and adventitia. Submucosal glands lay in 
the deeper layers of the lamina propria and within the submucosa. A layer of obliquely
arranged smooth muscle surrounds the lamina propria. The cartilage rings of the 
trachea transform into irregularly shaped cartilage plates in bronchi. Bronchioles lack 
cartilage and glands, but the amount of smooth muscle is proportional to the size of the 
bronchiolus. Alveolar ducts are surrounded entirely by alveoli. Ducts branch into three 
or more alveolar sacs. No smooth muscle is present at this level. The alveolar 
epithelium is composed mainly (95%) of remarkably thin squamous epithelial cells 
(type I pneumocytes), with the remainder being cuboidal epithelial cells (type II 
pneumocytes). Alveolar sacs enclose in their lumen macrophages, the primary function 
of which is defensive. (Figure 1). 
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Figure 1. A drawing of respiratory histology at three different levels (Reprinted 
and modified with the permission of Kustannus Oy Duodecim; originally 
published in Keuhkosairaudet; eds. V.Kinnula, P.Tukiainen, L.Laitinen 2. edition 
2000).
5.2. Pathogenesis of canine pulmonary eosinophilia (PE)
Canine PE is a bronchointerstitial inflammatory pulmonary disease 
characterized by eosinophilic infiltration into the lung interstitium and the bronchial 
epithelium. PE is often associated with peripheral blood eosinophilia (Gibbs and 
Anderson 1990, Corcoran et al. 1991, Taboada 1991). Several terms, including 
pulmonary infiltrates with eosinophilia (PIE), eosinophilic pneumonia, pulmonary
hypersensitivity, and eosinophilic bronchopneumopathy, have been used to describe 
the same syndrome (Gibbs and Anderson 1990, Corcoran et al. 1991, Taboada, 1991, 
Clercx et al. 2000). The etiology of PE is unclear, remaining in many cases unknown. 
Parasitic, bacterial, allergic, and fungal agents as well as a reaction to drug exposure 
have been described as potential etiologic agents (Noone 1986, Bauer 1989, Taboada, 
1991). Recently, hypersensitivity mechanism I has been suggested to be involved in 
the etiology (Clercx et al. 2002).
Eosinophilic inflammation can involve primarily the airways or the 
interstitium, or both simultaneously (Dungworth 1993, Dail 1994, Hawkins 1998,
Clercx et al. 2000). Histopathological changes at the bronchial level include an 
edematous and hyperemic lamina propria and infiltration of eosinophils accompanied
by lymphocytes, macrophages, and plasma cells. The epithelium is highly susceptible 
to sloughing (Dungworth 1993, Clercx et al. 2000). When inflammation also occurs at 
the alveolar level, it causes type I alveolar epithelial cell necrosis and sloughing, 
leading to a temporary denuding of the alveolar BM during acute inflammation.
Eosinophils, as a major inflammatory cell type, gather into alveolar spaces and the 
interstitium. Elevated numbers of macrophages, lymphocytes, mast cells, neutrophils,
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and epithelial cells have also been found in PE dogs’ BALF, and inflammatory cells 
also in the broadened interstitium (Dungworth 1993, Dail 1994). Proteinaceous
exudates accumulate in the alveolar spaces, but the lung architecture is preserved.
Cuboidal type II cells begin to line the denuded alveolar walls. Type II cells transform 
into type I cells, returning the normal structure after the inflammation, with the
exception of chronic cases in which changes can proceed to collagen deposition and
fibrosis (Dungworth 1993).
Typical clinical findings in canine PE include lower respiratory tract
symptoms, eosinophilia in BALF and tracheal fluid, densities in thoracic radiographs, 
occasional blood eosinophilia and eosinophilic infiltration of the bronchial mucosa.
The increase of absolute white blood cell count has been described to be 3- to 700-fold 
that of healthy dogs, and neutrophilia may also occur (Bauer 1989, Corcoran et al. 
1991, Taboada 1991, Clercx et al. 2000, 2002). 
The treatment of choice for canine PE is corticosteroid medication at a 
decreasing immunosuppressive dose unless a cause for the syndrome can be found and 
removed. Response to treatment is usually good and prognosis favorable; however, 
relapses are not uncommon (Hawkins 1995b, Johnson and Padrid 2000, Clercx et al. 
2000, Norris and Mellema 2004). 
5.3. Bronchoalveolar lavage (BAL) 
The epithelial lining fluid (ELF) is a thin layer of fluid on the luminal surface
of the respiratory tract. Lavage fluid contains both lavage fluid and ELF, and the 
dilution of ELF occuring during BAL could be determined by measuring a dilute 
present in ELF but not in lavage fluid. Additionally, the solute in ELF should also be
the same or a constant fraction than in the plasma. Endogenous ELF solutes e.g. urea, 
albumin and protein have been utilized allthough there are major defects in their use. 
The urea method is likely to overestimate ELF because of diffusion from the 
circulation, which occurs to varying degrees in different patient groups. BAL albumin
and protein levels are elevated in patients with a variety of interstitial diseases,
reflecting the epithelium/endothelium barrier disturbance. Development of a practical 
method for the ELF assessment is still elusive and the emperical expression of BALF 
solute results as per milliliter of aspirate remains the most useful method (Ward et al., 
1999).
Bronchoscopy is indicated when thoracic radiographs reveal either diffuse or 
localized abnormal findings and a diagnosis cannot be set by other methods.
Depending on the lesion, BAL or biopsies are performed. BAL has been established to 
be a clinically useful procedure. Hawkins et al. (1995) found BAL to correlate 
definitely or supportively with clinical diagnosis in 75% dogs with alveolar or 
bronchial radiographic patterns, or the presence of pulmonary mass.
BAL can be obtained either with a bronchoscope or with a blind method using 
a tube or catheter (Hawkins et al. 1995, McCauley et al. 1998, Andreasen 2003). 
However, bronchoscopic method is considered superior because it allows a direct view
of the airways for estimation of pathological changes on the epithelial surface, and 
specimens can be collected directly from the desired site.
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The volume of the infused sterile isotonic saline varies considerably between
different studies. Small-volume fluid washes utilizing weight adjusted 1-2 ml/5 kg 
(Cowell et al. 1999) or total amounts of 50-140 ml (Cohen and Batra 1980, Hawkins 
1990) are more commonly recommended than large-volume (500 ml) washes (Pinsker
et al. 1980). Small-volume washes are reported to yield a greater total cell count per 
milliliter and higher polymorphonuclear leukocyte concentration than large-volume
washes, which contain higher bronchial cell concentrations (Pinsker et al. 1980). 
Pooling and combined analysis of collected aliquots are generally used. However, first 
aliquots have been reported to contain greater contribution from larger airways, 
reflected in higher neutrophil and epithelial cells propotions, than later boluses 
(Pinsker et al. 1980, Hawkins and Berry 1999). The recovered propotion of instilled 
fluid ranges between 50% and 90 % in healthy dogs; however, this propotion is clearly 
lower in dogs with diseased airways (Hawkins 1990, Clercx et al. 2002).
Although therapeutical lavages with large volumes of saline are rarely used in 
dogs; a recent report describes treatment of a dog with alveolar proteinosis using lung 
lavage (Silverstein et al. 2000). 
5.3.1. Laboratory processing of bronchoalveolar lavage fluid (BALF)
When stored on ice, BALF must be analysed immediately. For later analyses, 
BALF can be stored in an ethylenediaminotetra-acetic acid (EDTA) tube (Hawkins 
1990, Andreasen 2003). Mucus filtration, speed, duration, and number of 
centrifugations, as well as washing of cells, cytocentrifugation, and cell counting 
method all affect cellular results and can therefore cause distortion in the BALF 
findings (Saltini et al. 1984, Klech and Pohl 1989, Andreasen 2003). For example,
performing centrifugation before cytocentrifugation causes an 18-34% loss of human
BALF cells (Saltini et al. 1984, Mordelet-Dambrini et al. 1984).
Differential cell counts can be assessed from stained slides obtained by 
cytocentrifugation, manual preparation by smears, settling on slides, or by the use of 
Millipore filters. Each method may affect the results (Rennard et al. 1998).
A quantitative bacterial culture helps in differentiating pathogens from 
contaminants, as shown by Peeters et al. (2000), who compared quantitative culture 
with gram-stain intracellular bacteria counts from BALF specimens. A minimum of 
1.7 x 103 colony-forming units (CFU) per milliliter was considered the threshold for 
defining clinically relevant bacterial growth.
5.3.2. Cellular content in BALF 
There are some reports of the cellular content in healthy dogs’ BALF (Rebar et al. 
1980, Pinsker et al. 1980, Hawkins 1990, Vail et al. 1995, Hawkins 1998, Norris and 
Mellema 2004). Cellular content is expressed more often in relative values than in
absolute values. Relative values seem to be more constant than the absolute values of 
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nucleated cells, and the maximum is often referenced as 500 cells per microliter
(Hawkins 1998, Andreasen 2003, Norris and Mellema 2004).
Mean relative counts for macrophages are 65-80%, for lymphocytes 6-14%, for 
neutrophils 1-5%, for eosinophils 3-6%, for mast cells 1-2%, and for epithelial cells 
0.8-1% (Rebar et al. 1980, Vail et al. 1995, Hawkins 1998). Results may deviate from 
these values if only leukocytes are included. In addition to differential counting, cells 
should be analyzed qualitatively; macrophages for activation, phagocytized material,
lymphocytes, and plasma cells for reactivity, neutrophils for intracellular bacteria and
degenerative changes, and noninflammatory cells for malignancies or infectious agents
(Hawkins 1990).
The repetition of lavages at short intervals (24 hours) causes transient influx of 
neutrophils in BALF (Cohen and Batra 1980), but at longer intervals (3 weeks) no 
such changes have been noticed (Pinsker et al. 1980).
Few studies have reported on the cellular content of BALF in PE dogs. Relative 
eosinophilic inflammation predominates, but other cells are also present (Hawkins 
1995b, Johnson and Padrid 2000, Norris and Mellema 2004). 
5.3.3. Safety of BAL procedure
Patients for the BAL procedure must be selected carefully. BAL cannot be 
performed without risks in patients with respiratory distress mainly because of the 
requirement for general anesthesia and the transient hypoxemia (Hawkins 1999). 
However, in certain situations, the diagnosis or the cure cannot be achieved with less 
invasive techniques, and in these cases BAL is an alternative to thoracotomy and may
be chosen after all pros and cons are weighed. 
The potential acute hazard of bronchoscopy and BAL to dogs is decrease in 
arterial blood oxygen concentration caused primarily by decreased compliance and 
ventilation-perfusion mismatching (Hawkins 1999). This can usually be avoided by 
providing oxygen supplementation. Chronic effects of the large volume fluid lung 
lavage procedure have been investigated by Muggenburg et al. 1972, but minimal
long-term risks were observed based on postmortem examinations and 
cardiopulmonary and lung function tests. Thus, in general, this procedure is considered 
safe for the selected patients population. 
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5.4. Matrix metalloproteinases (MMPs)
The lung extracellular matrix (ECM) is made up of several macromolecules
including collagens, proteoglycans, matrix glycoproteins, fibronectin, laminins,
elastin, and connective tissue glycoproteins (Schwarz 1998). The main collagen types 
in the lung interstitium are types I and III, and to lesser degree types IV, and V 
(Davidsson 1990, O’Connor and FitzGerald 1994, Fukuda et al. 1995). The BM,
located between epithelial cells and the ECM, consists mainly of collagen IV, 
proteoglycans, and glycoproteins including laminins and nidogen.  MMPs are a family
of zinc-dependant extracellular and cell surface associated proteinases capable of 
cleaving almost all ECM and BM protein constituents. At present, at least 24 MMPs
have been identified in vertebrates and grouped into subclasses based on substrate
specificity, sequence similarity, and domain organization. These include three 
collagenases (MMP-1, MMP-8, MMP-13), two gelatinases (MMP-2, MMP-9), four 
stromelysins (MMP-3, MMP-10, MMP-11, MMP-12), seven membrane-type MMPs 
(MT1-MMP, MT2-MMP, MT3-MMP, MT4-MMP, MT5-MMP, MT6-MMP, MMP-
23), two matrilysins (MMP-7, MMP-26), and others not classified in the previous
categories (Visse and Nagase 2003) (Table 1). MMPs share to a large extent common 
structural and functional elements but are produced by different genes. They are 
composed of a signal peptide, a prodomain, a catalytic domain with a zinc-binding 
site, and a hemopexin- or vitronectin-like domain linked to the catalytic domain by a
hinge region. Gelatinases MMP-2 and -9 also contain fibronectin type II inserts within
the catalytic domain, and MT-MMPs a transmembrane domain (Kähäri and Saarialho-
Kere 1999, Parks and Shapiro 2001, Ohbayashi 2002, Atkinson and Senior 2003).
MMPs are distinguished from other classes of proteinases by their dependence on 
metal ions and neutral pH for activity as well as by their common structural homology
including the sequence homology, the cysteine switch motif in the propeptide, and the 
zinc-binding motif in the catalytic domain (Visse and Nagase 2003). MMPs are 
secreted to extracellular milieu in a latent form, zymogens, induced by a response to 
exogenous signal and are proteolytically activated thereafter by cleavage to a truncated 
form with about 10 kilodalton (kDa) lower molecular size (Birkedal-Hansen 1993, 
Shapiro 1998, Kähäri and Saarialho-Kere 1999, Ohbayashi 2002). Majority of MMPs 
are de-novo expressed only after induction, and only presynthetized MMP-8 and 
MMP-9 are stored in secretory granules of neutrophils ready for rapid release and 
activation upon neutrophil degranulation (Kähäri and Saarialho-Kere 1999, Shapiro 
and Senior 1999).
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Table 1. Classification of matrix metalloproteinases (Sternlicht and Werb  2001, 
Acharya et al. 2004). 
Subgroup MMP Nomenclature
Interstitial collagenases MMP-1 Collagenase-1
MMP-8 Collagenase-2
MMP-13 Collagenase-3
Gelatinases MMP-2 Gelatinase-A
MMP-9 Gelatinase-B
Stromelysins MMP-3 Stromelysin-1
MMP-10 Stromelysin-2
MMP-11 Stromelysin-3
MMP-12 Metalloelastase
Matrilysins MMP-7 Matrilysin-1
MMP-26 Matrilysin-2, Endometase
Membrane type MMP MMP-14 MT1-MMP
MMP-15 MT2-MMP
MMP-16 MT3-MMP
MMP-17 MT4-MMP
MMP-24 MT5-MMP
MMP-25 MT6-MMP
MMP-23 CA-MMP
Others MMP-18 Collagenase-4 (Xenopus)
MMP-19 RASI-I
MMP-20 Enamelysin
MMP-21 CMMP (chicken)
MMP-22
MMP-27
MMP-28 Epilysin
The proteolytic activity is delicately regulated by transcriptional regulation, 
proenzyme activation, and inhibition of proMMP activation and MMP activity (Corbel 
et al. 2002). In addition, chemical agents (e.g. organomercurials), oxidative stress, 
serine proteinases such as plasmin and trypsin, and other MMPs such as MT-MMP
activate each other in a complex network (Sorsa et al. 1997, Brenneisen et al. 1997, 
Kähäri and Saarialho-Kere 1999, Moilanen et al. 2003, Holopainen et al. 2003). 
Microenvironmental changes including low pH and heat treatment, can also cause
activation (Visse and Nagase 2003). Activation of MMPs is stepwise in many cases 
and can be initiated by other already activated MMPs or by several serine proteinases 
that can cleave peptide bonds within the MMP prodomain (Sternlict and Werb 2001). 
In addition, bacterial proteinases can activate proMMPs (Sorsa et al. 1992). Figure 2.
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Figure 2. Activation of matrix metalloproteinases (MMPs) (Sorsa et al. 2004). 
The function of MMPs is very complicated and subtle. They are involved in normal
physiological processes as well as in pathological processes. Physiological processes 
include the normal turnover and maintenance of ECM proteins in connective tissue 
and BM and also in tissue remodeling and embryogenesis (Ohbayashi 2001, Parks and 
Shapiro 2001). Moreover, MMPs are engaged in the cell-cell and cell-matrix signaling.
MMPs are able to modulate the activity of a variety of nonmatrix proteins; MMP-7 for 
instance is responsible for the activation of prodefensin in the small intestine, thereby 
participating in the bacterial defense process (Wilson 1999). Several MMPs, including 
MMP-1, -2, -3, -11, and -7 can modulate the activity of many growth factors, 
cytokines, chemokines, and adhesion receptors through proteolytic cleavage.
Fragments of matrix proteins can act as chemoattractants (Levi et al. 1996, Haro et al. 
2000). MMPs can also process pro-inflammatory mediators, defensins, complement
components, cell adhesion molecules, and cell surface receptors participating in cell 
signaling and innate immunity (Parks and Shapiro 2000, Owen et al. 2004). Certain 
MMPs, such as MMP-8, MMP-9, and MMP-7, can exert anti-inflammatory or 
defensive characteristics (Parks and Shapiro 2000, Owen et al. 2004). 
The cellular sources of different MMPs have been investigated widely. MMPs 
are usually derived from different pulmonary inflammatory cells, such as alveolar
macrophages, neutrophils, and eosinophils, in addition to resident cells including 
bronchial epithelial cells, Clara cells, alveolar type II cells, fibroblasts, smooth muscle
cells, and endothelial cells (Perez-Ramos et al. 1999, DiGirolamo et al. 2000, Segura-
Valdes et al. 2000, Wakefield 2000, Imai et al. 2001, Prikk et al. 2001b, Wahlgren et 
al. 2001). The expression rates of MMPs differ between stimulated and nonstimulated
conditions (Lee at al 2003, Woo et al. 2004). 
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5.4.1. The role of MMPs in diseases 
Excessive expression of MMPs contributes to the pathogenesis of different
pulmonary and nonpulmonary diseases. They are believed to play a role in the 
pathogenesis through degradation of ECM and BM. BM protein degradation might
cause influx of inflammatory cells and perturbation of the epithelial/endothelial
structure, whereas degradation of elastin and collagen could predispose to airspace 
enlargement (Senior and Shapiro 1999). Aberrant expression of MMPs has been 
associated with many destructive diseases including lung diseases, arthritis, 
periodontal diseases, atherosclerotic rupture, aortic aneurysm, and tumor progression
(Shapiro and Senior 1999). Lung diseases, with excessive amounts of MMPs include 
equine and human COPD (Segura-Valdez et al. 2000, Parks and Shapiro 2001, Raulo 
et al. 2001a, 2001b), human asthma (Prikk et al. 2002), bronchiectasis (Sepper et al. 
1994, 1995, Prikk et al. 2001b), and various interstitial diseases (Hayashi et al. 1996, 
Suga et al. 2000, Henry et al. 2002). 
5.4.2. MMP-2 and MMP-9 (gelatinases) 
MMP-2 and MMP-9 belong to the group of gelatinases. Their key feature is 
that they readily digest the denaturated collagens, gelatins. These MMPs have some
differences in their capacity to cleave different types of collagens; MMP-2, but not 
MMP-9, can degrade native type I and II collagens (Aimes et al. 1998, Konttinen et al.
1998).
MMP-9, also known as gelatinase-B, is secreted from cells in a glycosylated 
92-kDa form and activated thereafter to 77- to 82-kDa and 68-kDa forms by a protease 
cascade (Birkedahl-Hansen et al. 1993, Sorsa et al. 1997). The most efficient activators 
of MMP-9 are probably human trypsin-2 together with MMP-3 (Sorsa et al. 1997, 
Cuzner and Opdenakker 1999). Dimeric forms of the 220-kDa proMMP-9 are 
commonly found (Triebel et al. 1992). The protein sequence of canine MMP-9 
displays similarities with human (79.6%), rat (72.0%), rabbit (80.6%) and bovine 
(82.3%) sequencies (Yokota et al. 2001). MMP-9 has been located in many different 
inflammatory cells such as macrophages (Lemjabbar et al. 1999, Raulo et al. 2001b), 
neutrophils (Dahlen et al. 1999, Raulo et al. 2001b), lymphocytes (Kumagai et al. 
1999, Raulo et al. 2001b), mast cells (Kanbe et al. 1999), and eosinophils (Kumagai et 
al. 1999). Pulmonary resident cells do not produce MMP-9 in the normal lung but can 
express various MMP-9 species under stimulation (Atkinson and Senior 2003). In 
these resident cells, MMP-9 is expressed in bronchial epithelial cells, Clara cells (Zuo 
et al. 2002), alveolar type II cells (Pardo et al. 1998), fibroblasts (Wilhelm et al. 1989, 
Warner et al. 2004), smooth muscle cells (Kenagy and Clowes 1994), endothelial cells 
(Schnaper et al. 1993), and submucosal cells (Fukuda et al. 1998, Hoshino et al. 1999, 
Raulo et al. 2001b).
MMP-9 plays a key and pivotal role in gelatin and type IV collagen
degradation but also has many other substrates such as elastin, collagen V, VII, X, XI, 
XIV, and fibronectin. MMP-9 participates in basal cell migration (Legrand et al. 
1999), ECM component digestion, and activity modulation of other proteases and 
cytokines (Shapiro 1998, Shapiro and Senior 1999). 
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MMP-2, or gelatinase-A, a 72-kDa gelatinase in its latent form, is converted
into 59- to 62-kDa forms during activation (Birkedahl-Hansen et al. 1993). The canine 
N-terminal amino acid sequence has been found to be 87% identical to human MMP-2
(Coughlan et al. 1998). MMP-2 is not readily activated by serine proteinases including 
trypsin-2 and plasmin (Sorsa et al. 1997); instead, the main activation of proMMP-2 
takes place on the cell surface mediated by MT-MMPs with the assistance of tissue
inhibitor of matrix metalloproteinase 2 (TIMP-2) (Wang 2000, Visse and Nagase 
2003). Macrophages as well as pulmonary structural cells, such as fibroblasts, 
pneumocytes, epithelial, and endothelial cells, synthesize MMP-2 (Ohnishi et al. 1998, 
Segura-Valdez et al. 2000, Corbel et al. 2002). MMP-2 shares mostly substrate 
specificities with MMP-9 but can also digest type I and II collagens similarly to the
classical collagenases (MMP-1, -8, and -13) (Aimes and Quigley 1995, Konttinen et 
al. 1998).
Elevated levels of MMP-9 have been reported in such pulmonary diseases as 
asthma, adult respiratory distress syndrome (ARDS), human and equine COPD, and 
bronchiectasis (Torii et al. 1997, Raulo et al. 1998, Segura-Valdez et al. 2000, Suzuki 
et al. 2004). In normal, healthy resting tissues, the production of MMP-9 is at a low 
level (Parks and Shapiro 2001). MMP-9 has been proposed to merely modulate
enzymes and cytokines to fine-tune both destruction and repair, and may even have a 
beneficial function in a subset of cells in the disease process, therefore not being 
heavily involved heavily in the ECM destructive processes (Atkinson and Senior 2003, 
McMillan et al. 2004). While few studies have focused on the role of MMP-2, its 
contribution has nevertheless been shown in inflammatory human lung diseases (Maisi 
et al. 2002). Increased levels of either MMP-2 or activated forms of MMP-2 have been 
found in lung diseases including experimental silicosis, COPD, bronchiectasis, asthma, 
and ARDS (Sepper et al. 1994, Torii et al. 1997, Perez-Ramos et al. 1999, Segura-
Valdez et al. 2000, Maisi et al. 2002). Similar to MMP-9, MMP-2 has also been 
reported to act as an effector and downregulator in inflammation: McQuibban et al. 
(2001), for instance, demonstrated that MMP-2 can diminish inflammation.
5.4.3. MMP-1, MMP-8, and MMP-13 (collagenases) 
Collagenases MMP-1, MMP-8, and MMP-13 make up a subgroup of MMPs. 
They readily cleave interstitial collagens I, II, and III at a specific site producing ¾ 
(?A)- and ¼ (?B)-degradation products (Visse and Nagase, 2003). They all digest 
fibrillar collagens, which then denature at body temperature and then are further
degraded by other MMPs including MMP-2 and MMP-9. Collagenases can also digest
a number of other ECM and nonECM molecules such as ?1-antitrypsin, ?2-
macroglobulin, plasminogen, and tumor necrosis factor (TNF) -? (Birkedal-Hansen 
1993, Shapiro and Senior 1998, Sternlict 2001). 
MMP-8, collagenase-2, has in its latent form a molecular weight of 75-80 kDa 
and in its active form 64 kDa (Tschesche et al. 1992). However, cellular sources affect 
the molecular weight depending on the degree of glycosylation, activation, and 
fragmentation (Hanemaaijer et al. 1997, Palosaari et al. 2000). MMP-8 is primarily
synthesized in polymorphonuclear leukocytes (PMNs), is matured in the bone marrow,
and stored in intracellular-specific granules. MMP-8 is secreted by selective 
degranulation of these granules and thereafter activated by reactive oxygen species 
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trypsin-2, chymotrypsin, cathepsin G, MMP-3, MMP-10, MMP-7, and MMP-14 
(Murphy et al. 1987, Sorsa et al. 1989, Goldberg et al. 1992, Knäuper et al. 1993, Ding 
et al. 1997, Moilanen et al. 2003, Holopainen et al. 2003). MMP-8 preferentially 
hydrolyzes type I collagen, the major ECM component of the lung (Crystal et al. 1991, 
Tschesche et al. 1992). In addition to neutrophils, MMP-8 has been identified not only 
in pulmonary monocytes/macrophages, bronchial and gingival/sulcular epithelial cells, 
keratinocytes, plasma cells, glandular cells and in oral cancer cells (Peres-Ramos et al.
1990, Tervahartiala et al. 2000, Wahlgren et al. 2001, Prikk et al. 2001b, Raulo et al. 
2001a, Moilanen et al. 2002).
MMP-13, i.e. collagenase-3, is secreted in a latent 60-kDa form, transformed
into an intermediate 50-kDa form, and finally processed into its active 48-kDa form 
(Knäuper et al. 1996). MMP-13 has a key role in the MMP activation cascade 
(Leeman et al. 2002).
MMP-13 has a wide substrate specificity. It effectively hydrolyzes type II 
collagen but is 5-6 times less efficient at cleaving type I or III collagen (Knäuper et al. 
1996, Lindy at al 1997, Leeman et al. 2002). In addition, MMP-13 degrades BM type 
IV collagen and laminin-5 (Ln-5) ?2-chain, proteoglycans, fibronectin, fibrillin,
versican, and tenascin C (Knäuper et al. 1996, Pirilä et al. 2003, Leeman et al. 2002). 
MMP-13 is considerably restricted in its tissue expression due to its very
efficient catalytic properties (Kähäri and Saarialho-Kere 1999). It has been found in 
pulmonary macrophages and in nonpulmonary cells including plasma cells and 
gingival epithelial cells (Perez-Ramos et al. 1999, Tervahartiala et al. 2000, Raulo et 
al. 2001a, Wahlgren et al. 2001, Kiili et al. 2002).
Increased collagenolytic activity has been shown in the pathological processes 
of equine COPD, murine experimental lung silicosis, and human bronchiectasis, 
COPD and emphysema (Sepper et al. 1995, Perez-Ramos 1999, Segura-Valdes 2000, 
Prikk et al. 2001b, Raulo et al. 2001a, Imai 2001). MMP-13 is expressed excessively 
in inflammatory diseases, such as equine COPD, and in experimental lung silicosis in
rats (Perez-Ramos et al. 1999, Raulo et al. 2001a, Mariani et al. 2002). Additionally, 
MMP-13 appears to be critical especially in bone metabolism and homeostasis as well 
as in tumor metastasis and invasion (Leeman et al. 2002). Recently, MMP-8 has been
found to exert unexpected anti-inflammatory characteristics in lipopolysaccharide
(LPS) induced lung inflammation in mice (Owen et al. 2004). 
5.4.4. Inhibition of MMPs 
5.4.4.1. Physiological inhibition of MMPs
The activity of MMPs can be inhibited by endogenous or exogenous synthetic
inhibitors. The endogenous inhibitors are known as TIMPs, and to date four TIMPs
(TIMP-1, TIMP-2, TIMP-3, TIMP-4) have been identified in vertebrates. They play a 
key role in maintaining the delicate balance between ECM deposition and degradation 
in different physiological processes. TIMPs appear in most tissues and body fluids, but 
TIMP-3 is the only member of the TIMP family which is found exclusively in the 
ECM (Gomez et al. 1997) TIMPs inhibit the active enzyme as well as regulate the
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activation process of MMPs. They form tight bonds with the activated MMPs,
resulting relatively heat-, and proteolytic-resistant complexes (Sorsa et al. 1997, Brew
et al. 2003, Lambert et al. 2004). TIMP-1 and -2 inhibit the activity of most MMPs, 
with the exception of MT1-MMP. TIMP-2 is a ten times more effective inhibitor of 
MMP-2 and MMP-9 than TIMP-1, and TIMP-1 is two times more effective against
MMP-1 than against other MMPs. TIMP-1 forms complexes preferentially with 
proMMP-9, and TIMP-2 and -4 with proMMP-2 (Goldberg et al. 1989). TIMP-3 
inhibits activity of MMP -1, -2, -3, -9, and -13. TIMP-4 inhibits the activity of MMP-2 
and MMP-7 more potently than that of MMP -1, -3, and -9 (Kähäri and Saarialho-Kere
1999). Recent studies have revealed that these proteins can also exhibit biological 
activities that affect cell proliferation and survival. These activities are distinct from
their interactions with MMPs or inhibition of MMPs (Crocker et al. 2004). 
The predominant nonspecific serum inhibitor is ?2-macroglobulin, which is 
also responsible for regulating various other proteinases, especially serine proteinases 
(Birkedal-Hansen et al. 1993).
5.4.4.2. Synthetic inhibitors of MMPs
Synthetic exogenous MMP inhibitors, such as GalardinTM, MarimastatTM,
BatimastatTM, and the gelatinase-selective CTTHWGFTLC-peptide (Belotti et al.
1999, Koivunen et al. 1999, Auge et al. 2004, Ramnath and Craeven 2004), are the 
target of much research activity, particularly in the pharmaceutical field. Extensive
investigations have examined their biological activities in tumor growth, invasion,
metastasis, and angiogenesis as well as in the diagnosis and treatment of inflammatory
diseases. Doxycycline and nonantimicrobial tetracycline derivatives (chemically
modified tetracyclines, CMT) possess anticollagenase activity (Golub et al. 1997, 
Golub et al. 1998). CMTs have been tested in vitro also in pulmonary epithelial lining
fluid in equine COPD (Maisi et al. 1999). Despite tremendous efforts over the last 
decade with multiple inhibitor classes, simple, safe, and effective drugs for inhibiting
individual MMPs have not yet emerged (Matter and Schudok 2004). The only 
inhibitor in clinical use is low-dose or subantimicrobial dose doxycycline which has 
been shown to be beneficial as adjunctive medication in human periodontal diseases 
(Golub et al. 1997, Golub et al. 1998, Emingil et al. 2004 a,b). 
5.5. Laminin-5 (Ln-5)
BM is a thin structure separating epithelial or endothelial cells from the 
adjacent tissue. It provides a physiological support for tissues, acts as a barrier for cells 
of different origin, and is involved in cell differentiation and migration as well as 
tissue repair and remodeling. BM also acts as a reservoir of plasma proteins, enzymes,
and growth factors (Yurchenco and O’Rear 1994). It consists mainly of collagen IV,
proteoglycans, and glycoproteins, including Lns and nidogen (Ekblom et al. 1998). 
Lns are involved in cellular movement, growth, and differentiation and act as 
integrating elements between the extracellular matrix and the cytoskeleton of epithelial 
cells (Perez-Arellano et al. 1993, Yurchenco and O’Rear 1994, Baker et al. 1994, 
Sannes and Wang 1997, Michelson et al. 2000, Ghosh and Stack 2000). Ln-5 consists 
of ?3-, ?3-, and ?2-subunits (Miyazaki et al. 1993, Matsui et al. 1995, Ekblom et al. 
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1998, Michelson et al. 2000), and is one of more than ten different Ln isoforms with 
molecular weight of 400-440 kDa in its intact form (Mizushima et al. 1998, Elkhal et 
al. 2004). Ln-5 is a major component of the anchoring fibrils in the hemidesmosome, a
specialized epithelial cell-ECM connection. When epithelial cells are detached from 
the BM, like alveolar epithelial cells in canine PE (Dungworth 1993) and bronchial 
epithelial cells in human asthma (Laitinen and Laitinen 1994), Ln degradation 
products, such as Ln fragment P1, can be released (Perez-Arellano et al. 1993, Behr et
al. 1995, Lemjabbar et al. 1999). Their levels have been reported to be increased in 
BALF of human diffuse interstitial lung disease, fibrosing alveolitis, ARDS, and 
severe asthma (Perez-Arellano et al. 1993, Behr et al. 1995, Torii et al. 1997, 
Lemjabbar et al. 1999).
Various MMPs, including MMP-2, -3, -8, -12, -13, -14, and -20, can process 
the Ln-5 ?2-chain into lower molecular weight fragments, referred to as ?2x with 
molecular weight of 80 kDa or less (Koshikawa et al. 2000, Pirilä et al. 2003, 
Koshikawa et al. 2004). This fragment can stimulate epithelial cell migration and 
induction (Giannelli et al. 1997, Koshikawa et al. 1999, Koshikawa et al. 2000, Pirilä
et al. 2003, Ogawa et al. 2004). MMP-8 also cleaves the Ln-5 ?2-chain, but the 
cleavage site is different from that of the other MMPs, and it does not induce epithelial 
cell migration (Pirilä et al. 2003). Using in situ hybridization, in situ zymography, and 
immunohistochemistry, the Ln-5 ?2-chain has been localized with MMP-2 and -13 in 
inflammatory odontogenic keratocysts, and also with MMP-2 in inflamed gingiva and 
inendogenously produced laminin-5 rich matrix (Mäkelä et al. 1999, Pirilä et al. 2001, 
Wahlgren et al. 2003). In addition, Kivelä-Rajamäki et al. (2003) and Emingil et al. 
(2004 a,b) have reported elevated levels of Ln-5 ?2-chain degradation products in oral 
inflammatory exudates in conjunction with increased levels of MMP-8.
.
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6. AIMS OF THE STUDY
This thesis examines the clinical and pathophysiologic changes present in the canine 
PE, with a special interest in MMPs and Ln-5 ?2-chain in BALF. These changes are 
compared to findings in healthy dogs. Specific aims were as follows: 
1. to establish reference values for cytologic examination of BALF and to study the 
effects of repeated lavages on lung and on results of cytologic BALF analysis in 
healthy dogs.
2. to describe clinical changes, the effect of BAL on arterial blood gas values, and the 
effect of therapy on canine PE.
3. to study the expression of airway and lung  inflammation in PE dogs’ BALF, with 
special reference to MMP-2, -8, -9 and –13, to compare these findings with those in 
healthy dogs’ BALF, to localize the cellular origin of the MMPs. 
4. to describe changes encountered in the BM by measuring levels of the Ln-5 ?2-chain
and its degradation products in BALF, comparing these in PE dogs and healthy dogs 
and in PE dogs before and after treatment.
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7. MATERIALS AND METHODS
7.1. Dogs 
7.1.1. Control dogs (I-IV) 
Sixteen healthy Beagles (11 females, 5 males; mean age 5.5 years, range 3-10 
years; mean weight 12 kg, range 8-18) were used for determination of BALF 
cytological reference values and for investigation of the effect of repetitive lavages on
pulmonary health and on BALF cytological values (I). All 16 dogs were lavaged once 
and 11 dogs a further six times at 5- to 7-week intervals (I). The study protocol was 
approved by the Animal Care and Use Committee of the University of Helsinki.
7.1.2. PE-dogs (II-IV) 
The study population of PE dogs consisted of 20 dogs (12 females, 8 males;
mean age 3.8 years, range 7 months to 9 years; mean weight 17 kg, range 4-37 kg) 
presented to the Veterinary Teaching Hospital, University of Helsinki with symptoms
and history of lower respiratory tract disease. All dogs had previously been treated
with antibiotics. In addition five dogs had received corticosteroids, three 
bronchodilatators, three other symptomatic cough medications, four diuretics and one
arterial dilatators for respiratory symptoms (II, Table II). All dogs had abnormal
findings on clinical examination and eosinophilia in BALF (II, Table VI). 
Eosinophilia in BALF was diagnosed when the number of eosinophils exceeded the
upper limit set in Study I. All 20 dogs were examined carefully for any clues of the 
etiology of pulmonary eosinophilia, but no other diseases, pulmonary or otherwise, 
were found. 
Twelve dogs were re-evaluated by a similar examination protocol one to four 
weeks after the treatment, and five were also relavaged at the control visit and one 
during the treatment.
7.2. Examination protocol and sample collecting (I-II)
A similar examination protocol, including medical history, clinical
examination, pulmonary radiographs, hematology and serum biochemistry panels, 
arterial blood gas analysis, fecal flotation tests, and bronchoscopy with BAL was
performed on all dogs. Control dogs underwent the same protocol initially; with the 
exeption that fecal parasite tests (dogs routinely dewormed twice a year) and 
radiographs were taken only before the first lavage.
Five control dogs (aged 8-10 years) in the repetitive lavage group were 
euthanized 3 weeks after the last lavage. 
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7.2.1. Symptoms and clinical examination (I-II) 
Same questions of general and respiratory symptoms were asked from all PE
dogs’ owners. A thorough clinical examination with inspection, auscultation, and 
palpation was carried out in all dogs prior to any other studies. 
7.2.2. Pulmonary radiographs (I-II) 
Ventrodorsal and left lateral thoracic radiographs of nonsedated dogs were 
taken after clinical examination at the initial visit and for 12 PE dogs at the control 
appointment after the treatment. For the 11 control dogs in the repetitive lavage group, 
radiography was repeated 2 weeks after the last BAL.
Two blinded examiners evaluated the radiographs independently for pulmonary
and other diseases. Pathological changes at the alveolar, interstitial, and bronchial 
levels in the lungs were graded using a scale from 0 to 3+ (0 normal, 1+ mild, 2+ 
moderate, 3+ severe), and a radiographic score was calculated by summing all pattern 
scores.
7.2.3. Blood samples (I-II) 
Venous blood was collected for hematological and biochemical analyses, and 
arterial blood samples were taken from the femoral artery for determination of arterial
oxygen (PaO2) and carbon dioxide pressures (PaCO2) before sedation. The second 
arterial sample was taken within 5 min after BAL but before reversal of sedation. 
Arterial gas analysis was carried out (ABL 300, Radiometer, Holliston, MA, USA),
and arteriao-alveolar oxygen gradients (A-aDO2) were calculated. 
7.2.4. Fecal samples (I-II) 
The fecal flotation test (Dryden and Bolka 1992) was used for intestinal 
parasite determination.
7.2.5. BALF (I-II)
After sedation with medetomidine (40 μg/kg intramuscularly (im.) (Domitor,
Orion Pharma, Turku, Finland) anesthesia was induced with propofol (1 mg/kg
iv.)(Rapinovet, Schering-Plough A/S, Kenilworth, UK), and bronchoscopy was 
performed using a fiberoptic bronchoscope (Olympus GIF type N30, Olympus, Tokyo, 
Japan). Additional oxygen was not administered. Both caudal lobes were lavaged with 
37ºC sterile saline (1 ml/kg twice/lobe), and the sample in a glass container was placed
on ice and processed immediately. Sedation was reversed with atipametzole (200 μl/kg
im) (Antisedan, Orion Pharma, Turku, Finland).
BALF was filtered through a one-layer cotton gauze, the volume measured and 
the recovered proportion of the total instilled fluid volume was determined. Four 500- 
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μl aliquots of native BALF were frozen at -70ºC. Cell count and viability in the 
original sample were assessed from the trypan blue stained sample (1:1) in the
hemocytometer. The remaining sample was centrifuged at 100 X g for 10 min, and the 
was supernatant separated from the cell pellet. Four 500-μl aliquots of supernatant
were frozen at -70ºC. The cell pellet was washed with 10 ml of phosphate-buffered 
saline (PBS), centrifugation was repeated, and the pellet was resuspended in 1 ml of 
PBS. Cell count and viability assessment were repeated and the result expressed in 
corresponding volumes. Aliquots containing 40 000 cells were cytocentrifuged 
(Cytospin 3, Shandon Scientific Ltd., Cheshire, UK) (250 X g for 10 min) on silicone-
coated slides. For the differential cell count, slides were stained with May-Grünwald-
Giemsa stain, and the rest of the slides were frozen at 70ºC for immunocytochemistry.
Differential cell counts for macrophages, lymphocytes, neutrophils, eosinophils, 
plasma cells, mast cells, and epithelial cells were obtained by counting 300 cells. From
the BALF cellular analysis results of all dogs, means, standard deviations (SDs), and 
95% confidence intervals (CIs) were determined and the 95% CIs of control dogs were 
used in the later studies as reference values (II, III, IV). Quantitative bacterial culture
(10 μl of BALF on a blood agar plate at 37°C for 48 h) was performed for 13 PE dogs; 
bacterial growth of 104 CFU/ml or more was set as the limit for infection. In addition,
all specimens were inspected for intracellular bacteria.
7.3. Histologic evaluation (I)
Lung samples from cranial (nonlavaged) and caudal (lavaged) lobes (three 
samples from each lung lobe) were collected and fixed in 4% neutral-buffered 
formalin immediately after euthanasia. Formalin samples were stained with 
hematoxylin-eosin (HE) and Masson-Trichrome stains. Health of the dogs was verified 
by complete postmortem examinations.
7.4. Assays 
7.4.1. Functional assays
7.4.1.1. Gelatin zymography (II) 
For the incubation (2 h at 22°C), native BALF and cell-free BALF samples
were mixed at a ratio of 2:1 with the sample buffer; containing 0.118M Tris (T-1378)
(Sigma, St. Louis, MO, USA), 64 mM H3PO4 (Art. 573) (Merck, Darmstadt,
Germany) 20% glycerol, 0.04 g/l bromphenol blue (Art. 8122) (BDH), and 6% sodium 
dodecyl sulfate (SDS, Prod. 44244) (BDH Chemicals Ltd., Poole, England), at pH 6.8, 
and then loaded onto a 10% SDS-polyacrylamide gelatin-containing gel (porcine skin 
gelatin 1 mg/ml, G-2625, Sigma Chemicals, St. Louis, MO, USA). A standard 
suspension of lysed equine neutrophils (Raulo and Maisi 1998) serving as an 
interassay control and a high-range molecular weight MW standard (Bio-Rad,
Richmond, CA, USA) were also loaded. Standardization of this method has been 
described previously (Raulo and Maisi 1998). The zymograms were run at 4ºC, 
incubated for 17 h at 37°C, and after staining with Coomassie blue the gelatinolytic 
activity was visualized by colouring as clear bands against a blue background.
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Zymograms were analyzed for total gelatinolytic activity and complex, proMMP-9,
active MMP-9, and MMP-2 forms (Mellanen et al. 1998). The gels were scanned 
(Scanjet 4C/T, Hewlett-Packard) and analyzed using an image analysis and processing 
system (Cream, Kem-En-Tek, Copenhagen, Denmark). Briefly, densitometric analysis 
was performed as follows: a linear standard curve drawn from the molecular standard 
lane provided the reference to which every band was compared in molecular weight 
assessment. The analysis program then drew a curve of each band based on the
densitometric properties expressed as arbitrary intensity units. Bands suggested by the
program were compared with the gel’s bands visible to the eye. The program 
compared each band with the equine neutrophil lysate standard, which was assigned a 
value of one hundred for total activity. Background intensity was subtracted from each
band’s curve, and densitometric results were gained from the program’s calculations
using the area mode. Total gelatinolytic activity was achieved by summarizing the 
results of different bands of a lane.
7.4.1.2. Type I collagen degradation (III) 
Both cell-free BALF (20 PE dogs, 16 controls) and native BALF (9 PE dogs 
with the highest collagen activity in cell-free BALF, 9 randomly selected controls)
samples at a 10-fold concentration with equal volume were used in the collagenolytic 
activity analysis (Raulo et al. 2001a). All samples were analyzed with and without 
activator (1 mM amino mercuric acetate (APMA)) treatment in parallel. Samples were
incubated with 1.5 μM triple helical type I collagen for 96 h at 22ºC in the dark. 
Incubation was terminated by adding Laemmli’s sample buffer and boiling, and 
degradation products were separated by the 10% SDS gel electrophoresis. Purified 
collagen I was used as a control. Gels were stained with Coomassie brilliant blue,
destained, scanned, and analyzed with an image analysis and processing system in a 
similar manner as in zymography. Four bands were visible, with the two highest bands 
representing intact collagen I ?1 and ?2 chains and the two lowest ¾-(?1 and ?2)
degradation products whose analysis results were therefore multiplied by 4/3.  The
proportion of degradation products was calculated by comparing it with intact collagen 
I.
7.4.2. Immunological assays
7.4.2.1. Immunocytochemistry (II, III) 
Immunocytochemistry analysis with Vectastain Rabbit/Mouse ABC Elite Kit 
(Vector Laboratories, Burlingame, CA, USA) was performed using either fresh (II) or 
frozen (III) samples on silicone-coated cytospin slides. Slides were fixed with acetone
for 10 min at 4ºC, washed three times in PBS, and incubated in 0.6% methanol-
perhydrol for 30 min at 22°C. Nonspecific binding was blocked with 2% normal goat 
(MMP-8, MMP-9) or horse (MMP-13) serum (1:50), primary antibody was applied, 
and samples were preincubated (III) for 1 h and then incubated at 4ºC overnight (II,
III). Specific rabbit polyclonal anti-human MMP-8 (1:250) (III), MMP-9 (1:500) (II),
and monoclonal anti-human MMP-13 (1:500) (III) antibodies were used (Oncogen,
Merck, Darmstadt, Germany) (Lauhio et al. 1994, Sorsa et al. 1994, Westerlund et al. 
1996, Sorsa et al. 1997, Lindy et al. 1997, Hanemaaijer et al. 1997, Mellanen et al. 
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1998, Kiili et al. 2002). For negative controls, primary antibodies were replaced with 1 
μg/ml (MMP-8-, MMP-9) rabbit or 0.2 μg/ml mouse immunoglobulin G. The 
background was decreased by the use of normal goat/horse serum (2%) in both the 
negative control and primary antibody solutions (III).  Secondary antibody (anti-
rabbit/anti-mouse 1:250, 30 min, 22°C) and avidin-biotin solution (1:125, 30 min,
22°C) were added, and slides were stained with chromogen-AEC (Dako, Glostrup, 
Germany) and counterstained with Mayer’s hematoxylin (Merck, Darmstadt,
Germany).
7.4.2.2. Western immunoblotting (II-IV) 
Western immunoblotting analysis was used to identify MMP-2, -8, -9, and -13
and to identify and quantify Ln-5 ?2-chain fragments. Samples were 20-fold (II, IV) or 
10-/20-fold (III) concentrated cell-free BALF. Each gel was loaded with equal
volumes of samples, molecular weight standard (Bio-Rad, Richmond, CA, USA), and
positive controls, the latter being either purified human polymorphonuclear 
supernatant for MMP-8, or purified human MMP-2, -9, or -13 (21,23-25/III), or intact 
rat Ln-5 ?2-chain (Plopper et al. 1996, Koshikawa et al. 1999, Kivelä-Rajamäki et al. 
2003, Pirilä et al. 2003).
Primary antibodies were the same as these used in immunocytochemistry, and 
for the detection of MMP-2, polyclonal anti-human MMP-2 (1:500) (Westerlund,
Mellanen, 21, 23-24/III) (II, III), and a 1:800 solution of rabbit polyclonal anti-human
Ln-5 ?2-chain were used (Pirilä et al. 2003) (IV). After electrophoresis on a 10% (II,
III) or an 8 % (IV) SDS-polyacrylamide gel, samples were transferred to 
nitrocellulose membranes electrophoretically. Nonspecific binding was blocked by 
incubation with 3% gelatin (Sigma, St. Louis, MO, USA) (II) or low-fat dried 5% milk
(Valio, Helsinki, Finland) (III). Following incubation with primary antibody 
(overnight at 22°C), secondary peroxidase-coated goat antirabbit antibodies (1:1000, 1 
h at 22°C) (Sigma) (II) and horseradish peroxidase-labeled donkey anti-rabbit (NA 
934) for MMP-8 (Amersham Pharmacia Biotech, Buckinghamshire, UK), sheep anti-
mouse antibodies (NA 931) for MMP-13 (dilutions 1:800) (Amersham Pharmacia
Biotech, Buckinghamshire, UK) (III), and goat anti-rabbit antibody (IV) were used.
Detection was carried out by using nitroblue tetrazolium and 5-bromochloro-3 indolyl-
phosphate stains in N-N-dimethylformamide (Sigma) (II) or with enhanced
chemiluminescence (ECL) detection reagents on radiographic films according to the
manufacturer’s instructions (IV) (Amersham Pharmacia Biotech, Buckinghamshire,
UK).
The membranes/films were scanned and analyzed qualitatively (II, III), or 
qualitatively and semiquantitatively (IV) in the manner described in section 7.4.1.1.
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7.5. Statistical methods 
Study I: Effects of repeated lavages on reference values were tested by repeated-
measures ANOVA. In case of a significant effect, the Bonferroni t-test was used to 
evaluate difference between successive sessions.
Student’s paired t-test was used to compare of arterial blood gas values, numbers of 
cells, and cell viability before and after lavage. Correlation coefficients were 
determined by using Pearson’s correlation analysis. 
Study II: A paired Student’s t-test was used to detect differences between pre-BAL and 
PaO2, PaCO2, and A-aDO2 values. Unpaired Student’s t-test was used for comparisons
between PE and healthy dogs’ BALF and blood values. In case of unequal variance, 
Welch’s correction was used. Pearson’s correlation coefficients (r) were calculated to
detect correlations between BALF and blood eosinophils as well as between BALF 
cell count and gelatinolytic activity. Spearman’s correlation test was used for 
correlations between radiographic scoring and blood eosinophil count, BALF 
cytology, and BALF enzyme activities. The Wilcoxon signed-rank test was used to 
compare PE dogs’ radiographic scores before and after treatment. The Mann-Whitney
U-test was used for comparisons between PE and control dogs’ radiographic scores.
Study III: The Mann-Whitney U-test was used to detect differences in collagenolytic 
activities between PE and control dogs as well as between cell-free BALF and native 
BALF. The Wilcoxon signed-rank test was used for comparisons between APMA-
treated and nontreated samples. Spearman’s correlation coefficients (r) were calculated 
to detect correlation between the percentage of degraded collagen I in cell-free BALF 
and the BALF cell count and differential cell count. 
Study IV: The Mann-Whitney U-test was used to assess the difference in of Ln-5 ?2-
chain immunoreactivities between PE and healthy dogs. Spearman’s correlation test 
was used for calculations of correlation coefficients (r) between BALF cellular counts 
and Ln-5 ?2-chain levels. Wilcoxon signed rank test was used for comparison between 
pre and post-treatment Ln-5 ?-2-chain levels. 
Statistical analyses were performed using commercial statistical software
programs (Statgraphics version 6.0, Manugistics, Rockville, MD, USA; SAS version
6.12, SAS Institute Inc., Cary, NC, USA (I); Prism 3.0, Graph Pad Software Inc., San
Diego, CA, USA (II-IV). A p-value ?0.05 was considered significant.
8. RESULTS
8.1. Symptoms, clinical examination, radiographs, blood and faecal
samples, and treatment response
8.1.1. Control dogs 
Control dogs expressed no symptoms, and no signs of respiratory or other 
diseases were found. Pulmonary radiographs showed minimal or no abnormal findings
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before the first and after the last lavage. Hematological and biochemical values, 
arterial blood gas analyses, and fecal flotation tests were not suggestive of any 
diseases. These results are presented in detail in Study I.
8.1.2. PE dogs 
Continuous cough was present in 95% of dogs, and four of these dogs also had 
other symptoms such as sneezing, dyspnea, and exercise intolerance. Fever (>39.5°C)
was noted in two dogs. The mean duration of symptoms was 20 weeks (range 3-80 
weeks) (II, Table II).
Thoracic radiographs revealed interstitial and bronchial densities in all PE
dogs, with the changes being severe in four and six dogs, respectively. The
radiographic score of healthy dogs differed significantly from that of PE dogs 
(p<0.001) (Table 2). PE dogs’ radiographic score correlated significantly with their 
BALF cell count (r=0.63, p<0.01), BALF eosinophil percentage (r=0.50, p<0.05) and 
eosinophil count (r=0.62, p<0.01), but not with their blood eosinophil count. The 
radiographic score was significantly lower after treatment (p<0.001). 
Table 2. Radiographic scores of pulmonary eosinophilia (PE) (n=20) and healthy
(n=13) dogs (A), and radiographic scores of PE dogs’ (n=12) before and after 
treatment (B).           * p < 0.05, ** p < 0.01, *** p < 0.001 
A.
Pattern Healthy dogs, mean ± SD PE dogs, mean ± SD 
Alveolar 0 ± 0 0 ± 0 
Interstitial 0.1 ± 0.3 1.5 ± 0.8 *** 
Bronchial 0.2 ± 0.4 1.7 ± 0.9 *** 
Radiographic score 0.3 ± 0.6 3.2 ± 1.6 *** 
B.
Pattern Pre-treatment, mean ± SD Post-treatment, mean ± 
SD
Alveolar 0 ± 0 0 ± 0 
Interstitial 1.7 ± 0.8 *** 0.5 ± 0.5 
Bronchial 1.9 ± 1.0 *** 0.5  ± 0.5 
Radiographic score 3.6 ± 1.8 *** 1 ± 0.9 
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Significantly higher values were noted in leukocytes, eosinophils and basophils 
(leukocytosis in 30%, eosinophilia in 50%, and basophilia in 55% of the PE dogs) 
(p<0.05, p<0.01, p<0.05) in blood differential count; other values did not differ from
those of healthy dogs (Table 3). Biochemical blood values were within the normal
range, and fecal samples were negative for parasites.
Table 3. Blood cytology in healthy (n=16) and pulmonary eosinophilia (PE) 
(n=20) dogs.         * p < 0.05, ** p < 0.01. 
Healthy dogs PE dogs 
. Mean?SD 95% CI Mean?SD 95% CI 
Packed cell volume (%) 46.6 ? 5.1 43.9 – 49.3 49.5 ? 5.0 47.1 – 51.8
Leukocytes
(cells x 103/μl)
10.2 ? 4.1 8.1 – 12.4 17.8 ? 12.3 * 12.1 – 23.6 
Segmented neutrophils
(cells x 103/μl)
7.3 ? 3.5 5.3 – 9.3 8.0 ? 4.1 6.0 – 10.0 
Band neutrophils
(cells x 103/μl)
0.03 ? 0.1 0.0 – 0.1 0.03 ? 0.1 0.0 – 0.1 
Lymphocytes
(cells x 103/μl)
2.2 ? 0.7 1.8 – 2.6 2.5 ? 1.8 1.6 – 3.3 
Monocytes
(cells x 103/μl)
0.5 ? 0.2 0.3 – 0.6 0.6 ? 0.4 0.5 – 0.8 
Eosinophils
(cells x 103/μl)
0.4 ? 0.3 0.2 – 0.5 6.7 ? 9.1 ** 2.1 – 11.2
Basophils
(cells x 103/μl)
0.0 ? 0.0 0.0 – 0.0 0.5 ? 0.8 * 0.1 – 0.8 
Clinical criteria (anamnesis, clinical examination, blood leukocyte and 
differential cell counts, thoracic radiographs, BALF cytology) were used for the
evaluation of the treatment response. Ten of 12 dogs re-evaluated had responded well 
to therapy. Two dogs still coughed, although radiographic changes and blood 
eosinophilia had decreased. Owners reported relapses in six dogs, which were then
remedicated. (II, Table II). 
These results are presented in detail in Study II, Tables II, III, and V. 
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8.2. Arterial blood gas analysis 
Mean ± SD of A-aDO2, PaO2, and PaCO2 were determined (Table 4). Arterial
pre-BAL PaO2 values measured at the first visit were significantly lower and A-aDO2
values higher in PE dogs than in healthy dogs (p<0.01 and p<0.001, respectively), 
while no difference was noted in PaCO2 levels. However, A-aDO2 and PaO2 values 
were within reference values, except in three PE dogs showing mild hypoxemia (<85
mmHg i.e. < 11.3 kPa). PaO2 values decreased and PaCO2 and A-aDO2 values
increased due to BAL procedure equally in both control (p<0.001, p<0.05, p<0.001, 
respectively) and PE dogs (p<0.001, p<0.01, p<0.001).
Repeated lavages in control dogs did not significantly affect A-aDO2, PaO2, or 
PaCO2 before BAL. Medication of PE caused no clear trend of an increase or decrease
in PaO2, PaCO2, and A-aDO2 values in the repeated lavage group.
Table 4. Results of arterial blood gas analysis in healthy (n=15) and pulmonary 
eosinophilia (PE) (n=18) dogs. Significant differences between healthy and PE 
dogs are indicated. * p < 0.05, ** p < 0.01, *** p < 0.001. 
Healthy dogs PE dogs 
. Mean?1 SD 95% CI Mean?1 SD 95% CI 
PaO2,  pre-BAL(mmHg) 105.2 ? 5.1 102.4 – 108.0 94.8 ? 10.4 ** 89.3 – 100.4
        postBAL(mmHg) 79.8 ? 10.3 74.1 - 85.5 74.7 ? 12.2 68.2 – 81.2 
PaCO2, preBAL(mmHg) 36.1 ? 2.0 35.0 - 37.3 36.9 ? 3.2 35.3 – 38.5 
          post-BAL(mmHg) 38.6 ? 1.5 37.8 – 39.5 39.8 ? 4.7 37.3 – 42.3 
A-aDO2, pre-BAL 
(mmHg)
2.5 ? 5.1 -0.3 – 5.3 16.1 ? 9.1 *** 11.2 - 20.9 
               post-BAL
(mmHg)
27.2 ? 9.6 21.9 – 32.5 35.9 ? 10.8 ?? 30.1 – 41.6
Differences due to BAL: 
Pre-BAL PaO2 – post-
BAL PaO2
25.5 ?16.7 15.8 – 35.1 18.6 ? 8.8 13.2 – 23.9 
Post-BAL A-aDO2 – 
pre-BAL A-aDO2
22.4 ? 15.5 13.5 – 31.4 22.5 ? 15.2 13.4 – 31.7 
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8.3. Bronchoscopic findings and cytological examination of BALF
8.3.1. Control dogs 
Bronchoscopy revealed no abnormal findings in the airways. 
Mean (± SD) recovery volume of instilled fluid was 63 ± 8%. No correlation 
was present between percentage of fluid recovered and A-aDO2 after BAL.
The recovered BALF (mean ± SD) 103.9 ± 68.5 cells/?l, and the resuspended cell 
pellet contained 61.8 ± 46.3 cells/?l. Alveolar macrophages (76.4 ? 48.2 cells/?l, 75.3 
± 6.9%) were the dominant cells detected. In order of decreasing frequency, the
remaining cells consisted of lymphocytes (15.0 ? 13.7 cells/?l, 13.3 ± 5.8%),
neutrophils (6.4 ? 7.1 cells/?l, 4.9 ± 3.8%), eosinophils (3.5 ? 5.0 cells/?l, 3.6 ± 
4.7%), mast cells (2.0 ? 1.8 cells/?l, 2.2 ± 1.7%), epithelial cells (0.6 ? 1.0 cells/?l, 0.6
± 0.7%), and plasma cells (0.2 ? 0.3 cells/?l, 0.3 ± 0.4%). In addition, 95% CIs for 
total and differential cell counts were determined (Table 5). 
Significant variations among repeated BAL sessions in control dogs were 
detected for percentages of macrophages, lymphocytes, and mast cells, whereas 
variations in cell counts and in percentages of neutrophils, eosinophils, plasma cells, 
and epithelial cells were not significant. Between two successive sessions, a significant 
difference in values was found only for mast cells (between BAL sessions 5 and 6), 
whereas all other differences were not associated with a specific dog or BAL session. 
A significant (p=0.001) number of cells were lost during the two 
centrifugations and one washing (range, 2-88%; mean ± SD, 59 ± 13%). Cell loss was 
not dependent on a specific BAL session or dog. Correlation analysis indicated a 
significant strong positive correlation between the number of cells in the original 
BALF sample and the number of cells in the resuspended cell pellet (r=0.87, p<0.001). 
No correlation was observed between body weight of a dog and cell count in the
original BALF sample.
Cell viability in the original BALF samples was 85 ± 17%. Cell viability
decreased significantly (p=0.01) with the two centrifugations and 1 washing to 71 ± 
11%.
8.3.2. PE dogs
The most typical bronchoscopic finding was increased airway secretion
(13/17). Mucosal hyperemia (5/17) or nodulation (3/17), blood-tinged secretions 
(2/17), and dynamic collapse of main-stem bronchi (2/17) were also noted (II, Table 
II). In the control bronchoscopy after the treatment, secretions had decreased markedly
in four dogs. Mean (± SD) recovery volume of instilled fluid was 46?11 %.
Bacterial culture of BALF was negative in PE dogs, and no intracellular 
bacteria were found in PE dogs’or in healthy dogs’ BALF samples. Airway cytology 
was also negative for parasites. 
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BALF cytology (mean ± SD) was 2272.9 ? 2353.0 cells/?l for total cells, 263.9 
? 242.3 cells/?l (20.9 ? 18.7%) for macrophages, 88.3 ? 63.5 cells/?l (7.1 ± 7.4%) for 
lymphocytes, 115.2 ? 163.6 cells/?l (8.2 ± 11.1%) for neutrophils, 1784.2 ? 2088.5 
cells/?l (62.3 ± 24.4%) for eosinophils, 17.6 ? 25.6 cells/?l (1.0 ± 0.9%) for mast
cells, 6.2 ? 10.9 cells/?l (0.5 ± 0.8%) for epithelial cells, and 0.6 ? 1.7 cells/?l (0.1 ±
0.3%) for plasma cells (Table 5). The cell count, the number and percentage of 
eosinophils, and the number of macrophages, lymphocytes, mast cells, neutrophils, 
and epithelial cells were significantly elevated in PE dogs’ BALF. Both the number
and the percentage of BALF eosinophils correlated positively with the number of 
eosinophils in blood (r=0.60, p<0.01) (r=0.74, p<0.01) (Study II, Table VI). The 
BALF cell count, eosinophil count, and percentage of eosinophils decreased after 
treatment (Figure 3).
Figure 3. BALF total cell count (A), BALF eosinophil count (B), blood eosinophil 
count (C), and BALF eosinophil percentage (D) before (week 0) and after
treatment.
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Table 5. Cytological findings in bronchoalveolar lavage fluid of healthy (n=16) 
and pulmonary eosinophilia (PE) (n=20) dogs. * p < 0.05, ** p < 0.01, *** p < 
0.001.
Healthy dogs PE dogs 
Mean ? SD 95% CI Mean ? SD 95% CI 
Viability (%) 84.8 ? 17.3 76.1 – 93.4 90.9 ? 5.4 88.2 – 93.5 
Cell count
              (cells/?l)
103.9 ?
68.5
67.4 – 140.5 2272.9 ? 2353.0 ** 1102.7 – 3443.0 
Macrophages (%) 75.3 ? 6.9 71.8 – 78.7 20.9 ? 18.7 *** 12.1 – 29.6 
              (cells/?l) 76.4 ? 48.2 50.7 – 102.1 263.9 ? 242.3 ** 143.4 – 384.4 
Lymphocytes (%) 13.2 ? 5.8 10.3 – 16.1 7.1 ? 7.4 * 3.7 – 10.6 
             (cells/?l) 15.0 ? 13.7 7.7 – 22.3 88.3 ? 63.5 *** 56.7 – 119.9 
Neutrophils (%) 4.9 ? 3.8 3.0 – 6.8 8.2 ? 11.1 3.0 – 13.4 
             (cells/?l) 6.7 ? 7.1 2.6 – 10.2 115.2 ? 163.6 * 33.8 – 196.5 
Eosinophils (%) 3.6 ? 4.7 1.2 – 6.0 62.3 ? 24.4 *** 50.9 – 73.7 
             (cells/?l) 3.5 ? 5.0 0.8 – 6.2 1784.2 ? 2088.5 ** 745.5 – 2822.8 
Mast cells (%) 2.2 ? 1.7 1.3 – 3.0 1.0 ? 0.9 * 0.5 – 1.4 
             (cells/?l) 2.0 ? 1.8 1.0 – 3.0 17.6 ? 25.6 * 4.9 – 30.3 
Epithelial cells
                    (%)
0.6 ? 0.7 0.2 – 0.9 0.5 ? 0.8 0.1 – 0.9 
             (cells/?l) 0.6 ? 1.0 0.1 – 1.1 6.2 ? 10.9 * 0.8 – 11.6 
Plasma cells (%) 0.3 ? 0.4 0.1 – 0.5 0.1 ? 0.3 0.0 – 0.2 
             (cells/?l) 0.2 ? 0.3 0.1 – 0.4 0.6 ? 1.7 0.0 – 1.4 
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8.4. Histological samples 
Histological samples taken from the control dogs were typical of the lungs of 
aging dogs (Robinson and Gillespie 1973) with enlarged distal air spaces and atrophic 
interalveolar septa in all samples, and anthracotic pigment and some foci of interstitial 
fibrosis, in the cranial lung lobes in particular. Three dogs had minimal amounts of 
pulmonary mineralization. Numbers of inflammatory cells were normal. All the 
changes identified in the nonlavaged cranial lobes were similar to, or more prominent
than, changes in the lavaged caudal lobes (II).
8.5. Assays
8.5.1. Functional assays
8.5.1.1. Gelatin zymography (II) 
PE and healthy dogs’ native BALF and cell-free BALF revealed gelatinolytic 
activity in zymography. Five clear gelatinolytic bands were detected; two high 
molecular weight bands (>100 kDa) representing complex forms of gelatinase, one 
band proMMP-9 (range 84-92 kDa), one active MMP-9 (range 70-82 kDa), and one 
proMMP-2 (range 61-72 kDa) were identified. In addition, low molecular weight
bands (<50 kDa) were detected. All, except one, of the PE and healthy dogs’ samples
contained complex forms, proMMP-9, and proMMP-2. (Figure 4). Total gelatinolytic 
activity, complex forms, proMMP-9, and active MMP-9 were significantly elevated in 
PE dogs’ cell-free BALF (p<0.001, p<0.05, p<0.01, p<0.05, respectively) and native 
BALF (prior centrifugation) (p<0.01, p<0.01, p<0.01, p<0.05) as compared with 
healthy dogs’ BALF (Figure 5). Total gelatinolytic activity and MMP-9 level in cell-
free BALF correlated with BALF neutrophil count (r=0.83, p<0.0001) (r=0.80, 
p<0.0001), but not with any other cell counts in BALF.
Figure 4. Gelatin zymogram of cell-free BALF from a dog with pulmonary 
eosinophilia (PE) and from a healthy dog. 
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Figure 5. Relative gelatinolytic activities in cell-free BALF of dogs with
pulmonary eosinophilia (PE) (n=20) and healthy (n=16) dogs (mean ± SD).
Analyzed as total activity, complex forms, proMMP-9, active MMP-9, and MMP-
2. * p < 0.05, ** p < 0.01, *** p < 0.001. 
8.5.1.2. Type I collagen degradation (III)
Collagenolytic activity was detected in both PE and healthy dogs’ native BALF
and cell-free BALF samples with and without APMA treatment. PE dogs’ 
collagenolytic activity was significantly higher than healthy dogs’ activity in cell-free
BALF (p<0.001) and native BALF (p<0.05), and APMA treatment had no significant 
effect on the amount of collagen I degradation. Neither PE dogs’ nor healthy dogs’ 
collagenolytic activity in cell-free BALF differed significantly from that in native 
BALF (p=0.07, p=0.25; respectively) (Figure 6, Table 6). 
Figure 6. Collagen I degradation in PE and healthy dogs’ BALF with and without
APMA treatment. 
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Table 6. Collagenolytic activity before and after APMA treatment in healthy and 
PE dogs’ cell-free and native BALF, expressed as percentage of collagen I 
degraded. Values reported are medians (ranges).
PE dogs Healthy dogs 
Cell free BALF
(n = 20) 
Native BALF
(n = 9) 
Cell free BALF 
(n = 16) 
Native BALF 
 (n = 9) 
 + APMA 21.8 (5.8-44.8)*** 44.9 (0.0-95.8) 6.8 (0.0-31.2) 12.1 (0.0-34.3) 
- APMA 20.4 (7.1-39.9)*** 35.6 (0.0-100.0)* 7.3 (0.0-67.5) 18.2 (0.0-21.8) 
n, number of dogs 
APMA, aminophenyl mercuric acetate 
*  p < 0.05 as compared with healthy dogs
*** p < 0.001 as compared with healthy dogs
A significant positive correlation was noted between the percentage of 
degraded collagen I in the PE dogs’ cell-free BALF and the cell counts of BALF 
eosinophils (r=0.64, p<0.01), macrophages (r=0.64, p<0.01), lymphocytes (r=0.57, 
p<0.05), and mast cells (r= 0.70, p< 0.01) as well as the cell count of BALF (r=0.68, 
p<0.01). However, there was no significant correlation with the BALF neutrophil
(r=0.44, p=0.06) or epithelial cell (r=0.12, p=0.62) counts and the correlation with 
BALF plasma cell count was negative (r=-0.41, p=0.09). The peripheral eosinophil 
and leukocyte counts did not correlate with the collagenolytic activity in cell-free 
BALF (r=0.22, p=0.39; r=0.17, p=0.47 respectively) (Figure 7). 
Figure 7. Correlation between the percentage of degraded collagen I and
bronchoalveolar lavage fluid (BALF) neutrophil (A) and eosinophil (B) counts. 
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8.5.2. Immunological assays 
8.5.2.1. Immunocytochemistry (II, III) 
Major immunoreactivity for MMP-8 and MMP-9 was detected in BALF 
macrophages and epithelial cells, while no expression of MMP-9 was noted in BALF
eosinophils. MMP-13 was found in macrophages (Figure 8A, 8B). 
Figure 8A. Immunocytochemical stainings (A-D) and May-Grunwald-Giemsa
staining of PE dogs’ BALF cells (E). Negative control (A), MMP-13
immunopositive macrophages (B), MMP-8 immunopositive macrophages (C), 
MMP-8 immunopositive epithelial cells (D), and eosinophils in PE dog’s BALF
cytospin slide (E). Bar =  20 ?m.
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Figure 8B. Immunocytochemistry staining of BALF cells with an antibody 
against MMP-9. Immunopositive macrophage (A), immunopositive epithelial cell
(B), and   negative control (C). 
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8.5.2.2. Western immunoblotting (II-IV)
The main gelatinolytic proteinases were further identified by Western
immunoblotting to be MMP-2 and MMP-9 (II). Three different MMP-9 species with 
molecular weights of approximately 90-94 kDa, 69-75 kDa, and 54 kDa were 
identified. MMP-2 Western immunoblotting revealed two species with approximate
molecular weights of 72 kDa and 41 kDa (Figure 9 A).
MMP-8 species of four different molecular weights were found: >100 kDa, 75-
80 kDa, 40-50 kDa, and <30 kDa. MMP-13 species showed two different bands 
representing molecular weights of 60 kDa and 50-55 kDa (Figure 9 A).
Figure 9 A. MMP-9, MMP-2, MMP-8, and MMP-13 Western blot of BALF from 
a PE dog.  Molecular weights indicated on the left. 
Western immunoblotting of the Ln-5 ?2-chain (IV) revealed multiple immunoreactive 
species ranging from 31 kDa to 200 kDa, with mean sizes of >200, 159,126, 94, 73, 
53, 42, and 36 kDa (Figure 9B).
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Figure 9 B. Western immunoblot of laminin-5 ?2-chain immunoreactivities in
pulmonary eosinophilia (PE) dog (1), healthy dog (2), PE dog before (3) and after
(4) corticosteroid medication. Intact laminin-5 ?2-chain is demonstrated.
Mobilities of molecular weight markers indicated on the left.
The most frequent species in PE dogs’ BALF were 36, 53, and 94 kDa (in 
65%, 100%, and 75% of samples, respectively), and in healthy dogs’ BALF 53, 36, 
and >200 kDa (100%, 38%, and 31%, respectively). In healthy dogs’ samples, bands 
>90 kDa were extremely weak. Levels of total immunoreactivity and 36-kDa and 53-
kDa fragmented species were significantly elevated in PE dogs’ samples (p<0.01, 
p<0.01, p<0.05, respectively) as compared with healthy dogs’ samples. Corticosteroid 
treatment reduced the levels of fragmented Ln-5 ?2-chain 36-kDa (p<0.05) and 53-
kDa species (not significantly) in PE dogs’ BALF (Figure 10 A, B). 
No correlation was present between total Ln-5 ?2-chain immunoreactivity or 
any of the Ln-5 ?2-chain immunoreactivities and BALF total or differential cell
counts.
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Figure 10. Multiple species of laminin-5 ?2-chain immunoreactivities in 
bronchoalveolar lavage fluid (BALF) from pulmonary eosinophilia (PE) and 
healthy dogs (A). and PE dogs before and after corticosteroid treatment (B). Data
presented as mean ± SD.
A.
B.
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9. DISCUSSION
9.1. Clinical findings, blood samples, and thoracic radiographs 
The key clinical features of PE dogs were similar to those reported in earlier
studies; the PE dogs were young although the age range was broad, and the most
prominent clinical sign was persistent cough (Lord et al. 1975, Grauer and Riesendal
1977, Corcoran et al. 1991, Clercx et al. 2000). Peripheral blood eosinophilia was
noted in half of the dogs, and thus, is only suggestive for this disease. Approximately
equal percentage has been described by Corcoran et al. (1991) and Clercx et al. (2000). 
We found radiographic changes to mostly be interstitial and bronchial; the alveolar 
patterns noted in a previous study Clercx et al. (2000) (probably connected to bacterial 
pneumonia) were not seen here. 
9.2. Arterial blood gas analysis
Our PE dogs’ A-aDO2 and PaO2 values were within reference values, with only 
three dogs showing mild hypoxemia (King and Hendricks 1995). Had the lesions been 
more advanced at the alveolar level (detectable also in radiographs), changes in blood 
gases would likely have been detected more often, as has been noted in pneumonia
(Wingfield et al. 1997). This may also explain why the BAL procedure decreased the
PaO2 values and increased the A-aDO2 values equally in healthy dogs and PE dogs, 
and why the medication caused no clear trend of an increase or a decrease in PaO2,
PaCO2, and A-aDO2.
9.3. BAL and BALF
The recovery percentage of instilled fluid was lower in PE dogs than in healthy
dogs, consistent with the earlier findings of canine and human BAL procedures in
healthy and diseased patients (Hawkins 1990, Baughman and Rennard 1999, Clercx et 
al. 2002).
We were able to set reference values for healthy dogs’ BALF cytology. 
Reference values for BALF are dependent on the methods used in sample collection 
and in laboratory processing. However, these techniques have not been rigorously 
standardized in veterinary or human pulmonology. BALF laboratory analysis methods,
e.g.filtration of the sample to remove mucus prior to centrifugation, speed, duration,
and number of centrifugations, washing of cells, cytocentrifugation, and cell counting, 
differ between laboratories, causing variations in the results and their interpretation in
practice and in the research field (Saltini et al. 1984). We found that two
centrifugations and one washing caused significant cell loss, and a decrease in cell 
viability, as well as a large variation in these two variables among dogs. However, 
total cell counts of the original BALF and the resuspended cell pellet correlated 
significantly, and thus, reflected the cellular status of lavaged lobes. This differs from 
the study of Lapointe et al. (1994) who found that centrifugation does not cause
significant cell loss of equine BALF cells. However, their study used only one 
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centrifugation. Similar to us, they noticed marked variation between individual horses. 
In studies of human BALF cells, centrifugation and washing have caused cell loss of
18-34% (Saltini et al. 1984, Mordelet-Dambrine 1984). In view of these findings, we 
recommend that separate reference values should be used for processed and 
nonprocessed cell counts.  More reliable estimates of cellular content can, however, be
obtained by using counts from nonprocessed, native BALF samples.
We used weight-adjusted amount of lavage fluid; not used in all studies 
reporting reference values for canine BALF adjust for weight (Rebar et al. 1980, 
Pinsker et al. 1980, Mayer et al. 1990, Hawkins 1990, Vail et al. 1995). However, 
usually such studies have had dogs with a fairly narrow range of weight, in contrast to 
the range for entire canine species. Thus, the range of fluid per kilogram is also 
narrow. However, the amount of fluid per kilogram does affect cellular results; Pinsker 
et al. (1980) reported that a smaller volume (50 ml) lavage had a greater total cell 
count and concentration of neutrophils than a larger volume lavage (500-600 ml),
which in turn had a higher concentration of bronchial cells. Our BALF cellular counts
are comparable with those in most studies utilizing even somewhat higher fluid 
volumes and different laboratory and lavage procedures; the maximum cellular count
reported for healthy dogs is four times higher than the cellular count here (Vail et al. 
1995, Andreasen 2003). This difference is tolerable when values for comparison
healthy and PE dogs are compared because of the great cytological (20 times, II)
difference between these groups. However, differences with other respiratory diseases 
might be smaller.
BALF differential counts of healthy dogs are consistent with findings of 
previous studies (Pinsker et al. 1980, Rebar et al. 1980, Hawkins 1990, Vail et al. 
1995). Relative values, in particular, remain constant when same cell types are 
included in the differential count. However, the use of relative values limits the 
interpretation of actual counts, especially when the total cell count changes because of
a disease. Thus, our data suggest the concurrent use of both values. The most
remarkable findings in PE dogs’ BALF were the increased cell count and absolute and 
relative eosinophilia. Absolute eosinophil count together with increased cell count was 
considered better than relative count in distinguishing PE dogs from healthy dogs 
because no overlapping, noted in some relative eosinophil values, occurred. In 
addition, significantly elevated absolute numbers of macrophages, lymphocytes,
neutrophils, mast cells, and epithelial cells as well as elevated relative numbers of 
macrophages, lymphocytes, and mast cells were found in PE dogs’ BALF. The
increase of cells other than eosinophils is also noteworthy. These cells may act as
important inflammatory mediators as well, although eosinophils are the predominant
cell in canine PE. 
9.4. Effect of repeated lavages 
The effect of repeated lavages on the health of the dogs was also studied by 
examining BALF cellular results, arterial blood oxygen concentrations prior to BAL, 
radiologic findings of the lungs, and results of histologic examination of pulmonary
tissues. We found repeated lavages at 5- to 7-week intervals to be a safe procedure, not 
causing significant changes in cell counts, or permanent changes to the lavaged lung 
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based on the previous criteria. The incidental changes in relative counts of 
macrophages, lymphocytes, and mast cells were not associated with a specific dog or 
BAL session. Only once, a significant difference was noted in values between two 
successive sessions (mast cells in sessions 5 and 6) indicating that the repetition of
lavage did not affect markedly on cell counts. 
In previous studies, transient 48-h BALF neutrophilia has been described in 
dogs, horses, sheep, and monkeys after BAL, with changes in BALF cell types in 
sheep returning to baseline within 1-3 weeks after lavage (Cohen and Batra 1980, 
Woodside et al. 1983, Sweeney et al. 1984, Carre et al. 1985, Haley et al. 1989). The 
equal effect of BAL on healthy and PE dogs’ PaO2 and A-aDO2 values enables the
bronchoscopist to predict changes in oxygenation and thereby to evaluate safety of the 
procedure as well as the need for oxygen supplementation beforehand. 
9.5. Etiology of PE 
Dogs with PE represented 35% of all dogs undergoing BAL during the 
collection period. Attempts to find the primary etiology were made, investigating such 
factors as drug exposure, parasitic, bacterial, and fungal infections, and as a result 5 of 
25 dogs were excluded from the study because a possible cause for eosinophilia 
(intestinal/nasal parasites in 3 dogs; bacterial infection of the lower respiratory tract in 
2 dogs) was identified. In the remaining PE dogs, no nonrespiratory diseases capable 
of causing eosinophilia were found. In several previous studies, simultaneous
dirofilariasis has been associated with PE (Lord et al. 1975, Calvert and Losonsky 
1985, Halliwell and Gorman 1989). We did not, however, observe any signs of 
dirofilariasis. This was expected because all dogs were of Finnish origin, and Finland 
is not an endemic area for heartworm. Other parasites, (e.g. Filaroides spp.,
Crenosoma vulpi, Angiostrongylus vasorums) possibly capable of causing PE, were 
also not found in these 20 remaining dogs in bronchoscopy, BALF cytology, or fecal 
flotation tests. None had a bacterial infection in the lower respiratory tract based on 
quantitative culture and the search for intracellular bacteria in BALF samples.
However, all of our dogs had had previous antimicrobial therapy, which might have 
affected culture results but not BALF eosinophilia. In two dogs excluded from the
study, bacterial infection may have been the cause of PE, as has been suggested in 
some earlier studies (Grauer and Riesendal 1977, Hawkins et al. 1995, Clercx et al. 
2000). Aspergillosis and drug exposure as causes for PE were not very probable. 
Aspergillosis can cause a variety of pulmonary lesions, including PE, in humans, and 
drug exposure is also etiological factor for PE in humans, and perhaps in dogs as well 
(Noone 1986, Bauer 1989, Bain 1996, Clercx et al. 2000). However, proper control 
studies are needed to confirm these etiologies. Here, neither of these etiologies was
suspected because Aspergillus was not found in any BALF cytology samples and none
of the dogs needed antifungal medication. In addition, all of the dogs had had their 
symptoms prior to the administration of any medications, and there had also been 
medication-free periods during the disease.  Based on the tests conducted, unknown or 
allergic etiologies were the only ones remaining. Allergy tests or hyposensitization 
treatments were not, however, performed. A potential role has been suggested for type 
I hypersensitivity (Suter 1984, Bauer 1989, Clercx 2002), but confirmation requires 
further studies. The remaining 20 dogs in our study were thus characterized as PE dogs
with unknown or allergic etiology. 
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9.6. Recovery of PE
The recovery of dogs from PE was followed by clinical examinations,
radiographs, hematology, arterial blood gas analysis, and BALF analysis. The BALF 
cellular and eosinophil absolute and relative counts were considered useful in the 
recovery evaluation. At least one of these markers of inflammation decreased during 
the medication period, although some abnormal values were still noted. A longer 
follow-up would reveal whether values return to normal levels or remain elevated 
despite the disappearance of clinical signs. Radiography was superior to hematology
because hematological changes were lacking in half of the dogs and because the 
intensity of radiographic findings correlated with absolute and relative counts of 
BALF eosinophils. The overall response to therapy was good, allthough six dogs were
reported to have relapsed later. These findings are consistent with previous reports of 
PE (Corcoran et al. 1991, Clercx et al. 2000).
9.7. MMPs
We detected significantly elevated gelatinolytic and collagenolytic activities in
PE dogs’ BALF compared with healthy dogs’ BALF, suggesting a pivotal role of these 
MMPs in canine PE. BALF was utilized instead of pulmonary tissue due to 
extensiveness of the lung biopsy collection method. Gelatinolytic and collagenolytic 
MMPs can together create degradation of the pulmonary tissue. Other MMPs and
proteinases, including such serine and cysteine proteinases, as trypsins, elastase, and 
plasmin, are likely involved in this process, acting in a cascade that activates and 
potentiates the catalytic effects of each component (Prikk et al. 2001a).
9.7.1. Gelatinolytic MMP-2 and MMP-9
The gelatinolytic proteinases, MMP-2 and -9, were present in both healthy 
dogs’ and PE dogs’ BALF samples, although the levels of total, complex, and pro- and 
active MMP-9 observed in PE dogs’ cell-free BALF were significantly higher than in 
healthy dogs’ specimens. MMP-2 levels were not elevated, and no active MMP-2 was 
detected. This suggests that the presence of MMP-9, particularly its activation, is one 
of the key molecular factors involved tissue destruction in PE. However, growing 
evidence also suggests that MMP-9 might be important in the migration of airway
inflammatory cells in vitro (Okada et al. 1997, Kumagai et al. 1999). Thus, MMP-9 
may play a dual role also in canine PE. Our findings of the contribution of MMP-9 are 
in accordance with earlier studies of equine and human pulmonary diseases showing 
the elevation of inductively expressed MMP-9 more frequently than constitutively
expressed MMP-2 (Sepper et al. 1994, Torii et al. 1997, Raulo and Maisi 1998, 
Segura-Valdez et al. 2000). An increase in the levels and activation of MMP-9 has also 
been described in equine COPD, in human asthma, and COPD and in induced asthma
(Raulo and Maisi 1998, Cataldo et al. 2003). 
In some lung diseases, MMP-2 may also be involved in tissue remodeling.
Elevated levels of MMP-2 have, for instance, been found in human emphysema and 
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COPD (Ohnishi et al. 1998, Segura-Valdes et al. 2000, Cataldo et al. 2000), but neither 
of these share common pathological features with PE.
To confirm the zymographic results, Western blot analysis with specific 
antibodies was applied (Westerlund et al. 1996, Sorsa et al. 1997). Three different 
MMP-9 immunoreactive species were observed. The species with the highest
molecular weight (90-94 kDa) represented proMMP-9, the second species (69-75 kDa)
the active form, and the third species (54 kDa) the proteolytically cleaved form 
(Westerlund et al. 1996, Sorsa et al. 1997). The two MMP-2 species visible
represented the complex (72 kDa) and the lower (41 kDa) proteolytically truncated
forms (Westerlund et al. 1996, Sorsa et al. 1997). In addition to pro- and active MMP-
9 and proMMP-2, low molecular weight bands (<50 kDa) were detected in 
zymography analysis evidently representing proteolytically processed MMPs (Lehti et 
al. 1998, Maisi et al. 2002). Gelatinolytic activity noted at 25-28 kDa may represent 
trypsin-like serine proteinases capable of participating in MMP activation cascades
(Prikk et al. 2001a).
Our findings suggest a major role for pro- and active MMP-9, and consistent 
with other publications, demonstrate that although MMP-2 and -9 are very similar in 
terms of structure and substrate specificity they appear to be involved in distinct ways 
in different diseases and animal species. Overall, inductively expressed and activated 
MMP-9 is abundantly present in inflammatory lung diseases in both dogs and humans
(Ohbayashi et al. 2002, Atkinson and Senior 2003).
9.7.2. Collagenolytic MMP-8 and MMP-13 
Involvement of collagenolytic MMPs in canine PE was shown in a similar
manner as involvement of gelatinolytic MMPs; PE dogs’ BALF demonstrated a high 
capability of degrading collagen I (the optimal collagen substrate with the least
variability in degradation capacity between collagenolytic MMPs) compared with
healthy dogs’ BALF, implicating a role for collagenases in the pathogenesis of canine 
PE. These findings support and extend previous studies reporting the contribution of 
collagenolytic MMPs, both MMP-8 and MMP-13, in the pathological processes of
various pulmonary diseases including equine and human COPD and human
bronchiectasis, emphysema, and asthma (Hoshino et al. 1999, Segura-Valdez et al. 
2000, Raulo and Maisi 2001, Prikk et al. 2001b, Imai et al. 2001, Prikk et al. 2002). 
Western immunoblotting was performed to identify subspecies of 
collagenolytic MMP-8 and MMP-13. The four bands in MMP-8 Western immunoblot
evidently represented complex forms of MMP-8 bound to endogenous MMP
inhibitors, such as ?2-macroglobulin and/or TIMPs, or MMP-8 dimers (>100 kDa), 
highly glycosylated PMN-type proenzyme colocalizing with the human PMN-type 
MMP-8 (75-80 kDa) isoform, nonPMN-type MMP-8 isoform (40-50 kDa) and 
fragmented isoforms of MMP-8 (< 30 kDa) (Nagase 1997, Hanemaaijer et al. 1997, 
Romanelli et al. 1999, Prikk et al. 2001). The expression of nonPMN-type MMP-8
species has been shown to be upregulated by proinflammatory mediators TNF-? and 
IL-1ß in mesenchymal cell lines including fibroblasts, endothelial cells, chondrocytes 
and plasma cells (Chubinskaja et al. 1996, Cole et al. 1996, Hanemaaijer et al. 1997, 
Wahlgren et al. 2001). Differences caused by the degree of activation, fragmentation,
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or glycosylation between various species are thus possible (Hanemaaijer et al. 1997, 
Kiili et al. 2002). Similar patterns of MMP-8 species released by degranulating
neutrophils (Ding et al. 1996, Ding et al.1997, Owen et al. 2004) have been shown, at 
least in part, to represent shedding of membrane-bound forms of MMP-8, some of 
which exert anti-inflammatory or defensive properties in acute lung injuries (Owen et 
al. 2004). 
APMA induces stepwise activation of MMPs by generating a reduction of 10- 
15 kDa in molecular weight by cleavage of the propeptide domain (Leppert et al. 
1995). In our Study (III), preincubation of the native or cell-free BALF with APMA 
had no significant effect on collagen I degradation capacity. This indicates that
collagenases are mostly in autoactive form in canine PE BALF. Oxidative stress is
associated with various lung diseases, such as human asthma and equine lower 
respiratory diseases (Bowler and Crapo 2002), and MMP-8 activation by reactive
oxygen species may not necessarily be related to the molecular weight changes (Sorsa
et al. 1989, Saari et al. 1990, Ding et al. 1996, Westerlund et al. 1996, Ding et al. 1997, 
Owen et al. 2004). Autoactive collagenolytic activity and activated collagenase species 
have both been previously noted in human and equine respiratory secretions, differing 
from guinea pig peritoneal lavage fluid eosinophil extract which requires chemical
activation before showing collagenolytic activity (Hibbs et al. 1982, Davis et al. 1984, 
Sepper et al. 1995, Raulo 2001a, Prikk et al. 2001b).
The two bands with MMP-13 immunoreactivities at approximately 60 kDa 
represent proenzymes, and the band at 50-55 kDa proteolytically activated species.
The lower of the two bands at 60 kDa correspond to the molecular weight the MW of 
human rheumatoid fibroblast proMMP-13 (Knauper et al. 1996, Kiili et al. 2002). 
9.7.3. Cellular sources of MMPs 
BALF represents the cells and their protein content in the final stage after
transmigration from the blood capillaries through the BM and the ECM into the 
alveolar space. During acute tissue inflammation, inflammatory cells are recruited 
from the circulation to the inflammation site (Corbel et al. 2000). Different proteinases 
degrading the tissue along the way play an important role in this phenomenon (Okada 
et al. 1997), and it is possible that the protein content of a cell may change during the 
transmigration.
We examined expression of MMP-8, -9, and -13 on BALF cytospin slides by 
immunocytochemical staining. Major immunoreactivities were recorded, focusing on 
the most frequent and morphologically easily identifiable cell types (macrophages,
epithelial cells, and eosinophils). The double-staining method for identifying groups of 
cells occuring less frequently (e.g. neutrophils) was not utilized. Therefore, in addition 
to the cells listed below, MMPs can probably be detected in other BALF cells and
pulmonary resident cells not examined here.
We localized immunoreativity for MMP-9 in alveolar macrophages and epithelial 
cells. Earlier studies of human and equine BALF samples have also reported similar
immunoreactivities for macrophages and bronchial epithelial cells (Fukuda et al. 1998,
Lemjabbar et al. 1999, Raulo et al. 2001b). The proteases of eosinophils have
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not been investigated extensively. Our findings of MMP-9-negative BALF eosinophils 
in dogs resemble those of Becky Kelly et al. (2000) in humans with allergic airway 
disease. Their findings correspond to ours, best when freshly prepared BALF cells are 
examined by immunocytochemistry and zymography (Becky Kelly et al. 2000). 
However, elevated levels of MMP-9 mRNA and protein in bronchial tissues have been 
detected in some earlier studies of human asthma (Ohno 1987). Shute et al. (1997) also 
reported MMP-9-positive eosinophils in bronchial epithelium in asthmatic humans by 
immunohistochemical analysis Shute et al. (1997) and Okada et al. (1997) MMP-9
activity in purified and isolated peripheral blood eosinophil supernatant and in the 
conditioned medium of a transmigration assay. Indirect support for eosinophil-derived 
MMP-9 in bronchial asthma is provided MMP-9 levels being correlated with the 
number eosinophil, in BALF/sputum/bronchial tissue of asthmatic patients (Hoshino et 
al. 1999, Lee et al. 2003, Warner et al. 2004). Thus, the lack of immunostaining may 
be due to rapid release of MMP-9 from eosinophils; this could also explain our finding 
of MMP-9-negative eosinophils. However, the highly significant correlation found 
between cell-free BALF total gelatinolytic activity and MMP-9 level and BALF
neutrophil count, but not eosinophils or any other cell counts in BALF (II), strongly 
suggests that eosinophils are not the primary source of MMP-9 in canine PE. 
MMP-8 was regarded mainly as a neutrophil-specific enzyme until recently 
(Chubinskaja et al. 1996, Cole et al. 1996, Hanemaaijer et al. 1997, Prikk et al. 2001b). 
We found MMP-8 immunoreactivity in canine epithelial cells and macrophages. These
results support previous studies reporting MMP-8 protein and mRNA expression in 
pulmonary monocytes/macrophages, bronchial epithelial cells, and glandular cells 
(Prikk et al. 2001b, 2002). No MMP-8 or MMP-13 immunoreactivity was noted in 
eosinophils, which is also in accordance with previous studies (Schlopov and Hasty
1998). However, correlation analysis did show a significant correlation between the 
percentage of degraded collagen I in BALF and BALF eosinophil count, supporting 
indirectly the hypothesis that eosinophils can also be sources of collagenolytic activity. 
Shlopov and Hasty (1998) have demonstrated that human blood eosinophils, showing 
negative immunostaining with MMP-8, MMP-13 and MMP-1 antibodies, contain a 
collagenolytic enzymes capable of degrading type I and II collagens similarly to 
MMP-1, -8, and -13. This is supported by earlier studies reporting collagenolytic 
activity in eosinophils against collagen types I and III (Hibbs et al. 1982, Davis et al.
1984). It has therefore been suggested that eosinophils produce an unknown enzyme
with collagenolytic activity, and this enzyme could also exist in PE dogs’ BALF 
eosinophils (Shlopov and Hasty 1998). Alternatively, eosinophils could act as
inflammatory mediators, secreting substances that induce collagenolytic activity-
possessing cells, such as epithelial cells, mast cells, plasma cells, and macrophages, to 
the inflammation site. Furthermore, collagenolytic activity probably also originates 
from residential cellular sources including bronchial epithelial cells, fibroblasts, type II 
pneumocytes, endothelial cells, and glandular cells (DiGirolamo and Wakefield 2000, 
Segura-Valdes et al. 2000, Imai et al. 2001, Prikk et al. 2001b, Wahlgren et al. 2001). 
However, numbers of these cells do not increase in the same manner as the numbers of 
inflammatory cells during the inflammation. Finally, MMP-2 and the soluble form of 
MMP-14 are able to degrade type I collagen similarly to MMP-1, -8, and -13 and thus, 
may contribute collagen I degradation (Konttinen et al. 1998, Fosang et al. 1998). 
Major MMP-13 immunoreactivity in PE dogs’ BALF was localized to the 
macrophages. This finding is in agreement with previous results in experimental
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pulmonary silicosis in rats and in equine COPD (Perez-Ramos et al. 1999, Raulo et al. 
2001).
9.7.4. Ln-5 ?2-chain
Ln-5 is a major component of the anchoring fibril in the specialized epithelial 
cell-ECM connection known as hemidesmosome. The breakdown of this link by the 
sloughing of the epithelial cells evidently causes the release of Ln-5 ?2-chain
degradation products into BALF, simultaneously leading to a temporarily naked BM.
We detected elevated levels of Ln-5 ?2-chain degradation products in BALF of PE 
dogs compared with control dogs, suggesting that epithelial injury results the contact 
between the BM and the alveolar/bronchial lumen during inflammation. At the 
histopathological level, this phenomenon of epithelial sloughing has been described in 
canine interstitial and bronchial lung diseases (Dungworth 1993, Dail 1994, Clercx et 
al. 2000), and is reflected in the increased number of epithelial cells in BALF in Study 
II. Study IV is the first to utilize measurement of Ln-5 ?2-chain degradation products
to indirectly assess epithelial sloughing. Perez-Arellano et al. (1993), Behr et al. 
(1995), and Lehmjabbar et al. (1999) have previously used measurement of a BM 
degradation product, laminin fragment P1, in BALF of humans with diffuse interstitial 
lung disease, fibrosing alveolitis, and severe asthma. In addition, increased amounts of 
intraepithelial cytoskeletal structures, namely cytokeratin 19, have been observed in 
BALF from patients with idiopathic pulmonary fibrosis (Inage et al. 2000). The 
improvement in PE dogs’ clinical, radiological, and hematological values described in
Study II is associated with decreases in total Ln-5 ?2- chain, 36-kDa, and 53-kDa 
fragmented Ln-5 ?2-chain species indicating a beneficial effect of corticosteroid
treatment on PE dogs’ epithelium. Based on the significant difference between healthy 
and PE dogs in these values, we considerer that the fragmented Ln-5 ?2-chain species
seemingly reflect an active ongoing inflammation which affects the BM. 
In studies II and III, we detected increased collagenolytic and gelatinolytic 
MMP activity in PE dogs’ BALF. Various MMPs, including the collagenolytic MMP-
8 and -13, and gelatinolytic MMP-2 but not MMP-9, can process the Ln-5 ?2-chain
into lower molecular size species (Giannelli et al. 1997, Pirilä et al. 2003). MMP-2 and 
-13 have been shown to be localized with the Ln-5 ?2-chain in inflammatory
odontogenic keratocysts, and MMP-2 also in the endogenously produced Ln-5-rich 
matrix (Mäkelä et al. 1999, Wahlgren et al. 2003). Kivelä-Rajamäki et al. (2003) and 
Emingil et al. (2004 a,b) reported elevated levels of Ln-5 ?2-chain degradation 
products in inflammatory oral fluid exudates collected around dental implantitis-, and 
periodontitis-affected teeth, and high MMP-8 levels in the exudates. The effects of 
MMPs on the laminin-5 ?2-chain are likely a consequence of collective release and
expression by many different cells at the inflammatory site. This speculation is based
on correlations not noted being present between BALF total or differential cell counts
and total, fragmented 36-kDa, or 53-kDa Ln-5 ?2-chain immunoreactivities. Earlier 
findings of pulmonary resident cells, such as bronchial epithelial cells, Clara cells,
alveolar type II cells, fibroblasts, smooth muscle cells, and endothelial cells, producing 
and releasing MMPs (Wilhelm et al. 1989, Kenagy and Clowes 1994, Pardo et al. 
1998, Yao et al. 1999, Prikk et al. 2001b, Zuo et al. 2002) support this notion. 
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We showed that Ln-5 ?2-chain degradation products decreased after treatment
with corticosteroids (IV). The mechanism of this downregulation of Ln-5 ?2-chain
degradation might be regulated by MMPs. Corticosteroid treatment has previously
been shown to downregulate MMPs in cell-culture conditions in vitro, as well as in 
clinical studies of human asthma (Shapiro et al. 1991, Bosse et al. 1999, Hoshino et al. 
1999). Emingil et al. (2004 a,b) have recently shown that MMP-inhibitor medication
(i.e. low-dose or subantimicrobial dose doxycycline) for periodontitis patients reduced 
pathologically elevated levels of both Ln-5 ?2-chain fragments and MMP-8 to healthy 
control level. We conclude that elevated levels of gelatinolytic and collagenolytic
MMPs indicate their involvement in pulmonary tissue disruption and shedding of Ln-5 
?2-chain degradation products from the BM in canine PE.
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9. CONCLUSIONS
1. Cytological reference values for BALF in healthy dogs were established. The 
lavage procedure repeated multiple times at 5- to 7-weeks intervals was shown to be
safe, with no apparent effects on dogs’ health or BALF cytology. 
2. PE dogs’ radiographs revealed bronchointerstitial densities. In BALF cell count, 
the number and percentage of eosinophils and the numbers of macrophages,
lymphocytes, neutrophils, mast cells, and epithelial cells were significantly elevated. 
Fifty percent of PE dogs had blood eosinophilia. The BAL procedure had an equal 
effect on PE and healthy dogs’ arterial blood gas values. Treatment of PE decreased 
BALF cell count, eosinophil count, and percentage and radiographic changes.
3. Gelatinolytic activity, associated primarily with proMMP-9 and active MMP-9, 
was elevated in PE dogs’ BALF compared with healthy dogs’ BALF. MMP-9 
immunoreactivity was predominantly found in macrophages and epithelial cells. 
PE dogs’ BALF also showed elevated collagenolytic activity compared with healthy 
controls. Western immunoblotting identified the presence of MMP-8 and MMP-13. 
Major immunoreactivity for MMP-8 was observed in macrophages and epithelial cells, 
and for MMP-13 in macrophages. These findings suggest that upregulation of both 
gelatinolytic and collagenolytic cascades contributes to tissue inflammation in canine
PE.
4. Fragmented Ln-5 ?2-chain species reflect an active ongoing inflammation
affecting the BM. This claim rests on the significant differences found between 
healthy and PE dogs the levels of total Ln-5 ?2-chain immunoreactivity, and 36-kDa
and 53-kDa fragmented species, as well as on the downregulating effect of 
corticosteroid treatment on these immunoreactivities. The Ln-5 ?2-chain fragmented
species could be considered as an adjunctive diagnostic marker of respiratory 
inflammation extending to the BM.
 53 53
11. Acknowledgments
This study was carried out mainly at the Department of Clinical Veterinary 
Sciences, Faculty of Veterinary Medicine, University of Helsinki. Some of the 
laboratory studies were performed at the Biomedicum Research Laboratory of the 
Department of Oral and Maxillofacial Diseases, Helsinki University Central Hospital
(HUCH), Institute of Dentistry, University of Helsinki. 
My deepest gratitude is due to my supervisors, Professors Päivi Maisi, Anna-
Kaisa Järvinen and Timo Sorsa. The late Päivi Maisi was the prime motivator behind
the research of inflammatory lung diseases at the faculty. Her commitment, endless 
energy, enthusiasm, and friendship are deeply missed. Science was fun with Päivi! I 
heartily thank Anna-Kaisa Järvinen for her ever-positive and supportive attitude
towards my work. Her vast experience in veterinary sciences has been invaluable 
during the course of this project. I am also extremely grateful to Timo Sorsa. Without
his guidance, scientific and technical expertise, and unselfish motives as a supervisor I 
could not have finished this work.
I owe my sincere thanks to Professors, Vuokko Kinnula and Lynelle Johnson 
for their constructive criticism and suggestions as official reviewers of my thesis. I 
also thank Carol Ann Pelli, for revising the language of this manuscript.
My warmest thanks are due to co-authors Seppo Saari and Taina Tervahartiala. 
Taina’s technical support in the laboratory has been indispensable: without her, I 
probably would still be there.
Many people at the Department of Clinical Sciences have supported and 
contributed to this work. I am indebted to Professor Elias Westermarck; who 
introduced me to the world of science already during my years as a veterinary student. 
My colleague, Irmeli Happonen, has been a true friend and an invaluable benefactor as 
Head of the Section of Internal Medicine in providing me with time to conduct my 
studies during hectic clinical periods. My gratitude is also due to Merja Ranta and 
Matti Järvinen for excellent technical assistance and to Arto Ketola for helping me 
with statistics. Many thanks to Saara Raulo, my co-worker during the past few years, 
for professional assistance and fruitful discussions. I warmly acknowledge former
veterinary students and present collaegues Mari Koivula, Päivi Katajavuori, Johanna
Rissanen, Jutta Salonen, for their contributions to this study.
My deepest gratitude and thanks are extended to my family. Kari, Rimma,
Senni, and Roni; you mean the world to me; a million thanks just for being there! My 
parents, Maria and Voitto Rajamäki, I thank for the support, help, and love I have got 
during my life. Without them and without the frog my mother caught for me, I would 
never have become a veterinarian! Loving thanks to my late sister, Eija Isaksson, for
friendship and care. I miss her enourmously. You and the rest of the kith and kin form
the steady foundation for my life.
This study was supported by the grants from the Finnish Foundation of Veterinary 
Sciences, the Helsinki University Research Funds, and the Helsinki University Central 
Hospital (HUCH) EVO grant (TI 020 Y 0002) 
 54 54
References
Acharya MR, Venitz J, Figg WD, Sparreboom A. Chemically modified tetracyclines 
as inhibitors of matrix metalloproteinases. Drug Resist Updat 2004; 7:195-208. 
Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase.
Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type 
I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem
1995;17:5872-5876.
Aimes RT, Li LH, Weaver B, Hawkes S, Hahn-Dantona EA, Quigley JP. Cloning, 
expression, and characterization of chicken tissue inhibitor of metalloproteinase-2
(TIMP-2) in normal and transformed chicken embryo fibroblasts. J Cell Physiol 
1998;174:342-352.
Andreasen CB. Bronchoalveolar lavage. Vet Clin North Am Small Anim Pract 2003; 
33:69-88.
Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir 
Cell Cell Mol Biol 2003;28:12-24. 
Auge F, Hornebeck W, Laronze JY. A novel strategy for designing specific gelatinase
A inhibitors: potential use to control tumor progression. Crit Rev Oncol Hematol
2004;49:277-282.
Bain GA, Flower CD. Pulmonary eosinophilia. Eur J Radiol. 1996;23:3-8. 
Baker SE, Hopkinson SB, Fitchmun M, Andreason GL, Frasier F, Plopper G, Quaranta 
V, Jones JC. Laminin-5 and hemidesmosomes: role of the alpha 3 chain subunit in 
hemidesmosome stability and assembly. J Cell Sci 1996;109:2509-2520. 
Bauer, T. (1989). Pulmonary hypersensitivity disorders. In Current Veterinary Therapy 
X, ed. R.W. Kirk, pp. 369-76. Philadelphia: WB Saunders Co.
Becky Kelly EA, Busse WW, Jarjour NN. Increased matrix metalloproteinase-9 in the
airway after allergen challenge. Am J Resp Crit Care Med 2000;162:1157-1161. 
Belotti D, Paganoni P, Giavazzi R. MMP inhibitors: experimental and clinical studies. 
Int J Biol Markers 1999;14:232-238. 
Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, 
DeCarlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 
1993;4:197-250.
 55 55
Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases:
evolution, structure and function. Biochim Biophys Acta 2000;7:267-283. 
Bowler RP, Crapo JD. Oxidative stress in allergic respiratory diseases. J Allergy Clin 
Immuno. 2002;110:349-356. 
Bosse M, Chakir C, Rouabhia M, Boulet L-P, Audette M, Laviolette M. Serum-matrix
metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio correlates with
steroid responsiveness in moderate to severe asthma. Am J Respir Crit Care Med 
1999:159:596-602.
Brenneisen P, Briviba K, Wlaschek M, Wenk J, Scharffetter-Kochanek K. Hydrogen 
peroxide (H2O2) increases the steady-state mRNA levels of collagenase/MMP-1 in 
human dermal fibroblasts. Free Radic Biol Med. 1997;22:515-524. 
Buisson AC, Zahm JM, Polette M, Pierrot D, Bellon G, Puchelle E, Birembaut P, 
Tournier JM. Platelet-activating factor increases the expression of metalloproteinase-9
in human bronchial epithelial cells. Eur J Pharmacol 1999;374:147-156. 
Calvert, CA., Losonsky, JM. Pneumonitis associated with occult heartworm disease in 
dogs. Journal of American Veterinary Medical Association 1985;186:1097-1098. 
Carre P, Laviolette M, Belanger J, Cormier Y. Technical variations of bronchoalveolar 
lavage (BAL): influence of atelectasis and the lung region lavaged. Lung 
1985;163:117–125.
Cataldo D, Munaut C, Noel A, Frankenne F, Bartsch P, Foidart JM, Louis R. MMP-2- 
and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and 
chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2000;123:259-267. 
Cataldo D, Munaut C, Noel A, Frankenne F, Bartsch P, Foidart JM, Louis R. 
Metalloproteinase-9 is increased after toluene exposure in the induced sputum from 
patients with toluene diisocyanate-induced asthma. Clin Exp Allergy 2003;33:113
Chubinskaya S, Huch K, Mikecz K, Cs-Szabo G, Hasty KA, Kuettner KE, Cole AA.
Chondrocyte matrix metalloproteinase-8: up-regulation of neutrophil collagenase by 
interleukin-1 beta in human cartilage from knee and ankle joints. Lab Invest 
1996;74:232-240.
Clercx C, Peeters D, Snaps F Hansen P, McEntee K, Detilleux J, Henroteaux M, Day 
MJ. Eosinophilic bronchopneumopathy in dogs. J Vet Intern Med 2000;14:282-291. 
 56 56
Clercx C, Peeters D, German AJ, Khelil Y, McEntee K, Vanderplasschen A, Schynts 
F, Hansen P, Detilleux J, Day MJ. An immunologic investigation of canine 
eosinophilic bronchopneumopathy. J Vet Intern Med. 2002;16:229-237. 
Cohen AB, Batra GK. Bronchoscopy and lung lavage induced bilateral pulmonary
neutrophil influx and blood leukocytosis in dogs and monkeys. Am Rev Respir Dis 
1980;122:239–247.
Cole AA, Chubinskaya S, Schumacher B, Huch K, Szabo G, Yao J, Mikecz K, Hasty
KA, Kuettner KE. Chondrocyte matrix metalloproteinase-8. Human articular 
chondrocytes express neutrophil collagenase. J Biol Chem 1996;271:11023-11026. 
Corbel M, Belleguic C, Boichot E, Lagente V. Involvement of gelatinases (MMP-2 
and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell 
Biol Toxicol. 2002;18:51-61. 
Corcoran, BM, Thoday, KL, Henfrey, JI, Simpson, JW, Burnie, AG and Mooney, CT. 
Pulmonary infiltration with eosinophils in 14 dogs. J Small Anim Pract 1991;32, 494-
502.
Cowell RL, Tyler RD, Meinkoth JH. Transtracheal/bronchoalveolar washes. In: 
Cowell RL, Tyler RD, Meinkoth JH, eds. Diagnostic cytology and hematology of the 
dog and cat. St.Louis: Mosby Inc, 1999;159–173. 
Coughlan, AR, Robertson, DH, Bennett, D, May, C, Beynon, RJ and Carter, SD. 
Matrix metalloproteinases 2 and 9 in canine rheumatoid arthritis. Vet Rec 1998;143, 
219-223.
Crocker SJ, Pagenstecher A, Campbell IL. The TIMPs tango with MMPs and more in 
the central nervous system. J Neurosci Res 2004;75:1-11. 
Crystal RG, Weibel ER, 1991. Structural organization of the pulmonary interstitium.
In: The Lung: Scientific Foundation, Crystal RG , West JB (Eds). Raven Press: New 
York, USA pp. 369-380.
Cuzner ML, Opdenakker G. Plasminogen activators and matrix metalloproteases,
mediators of extracellular proteolysis in inflammatory demyelination of the central
nervous system. J Neuroimmunol 1999;94:1-14. 
 Dahlen, B, Shute, J, Howarth, P. Immunohistochemical localization of the matrix
metalloproteinases MMP-3 and MMP-9 within the airways in asthma. Thorax 1999; 
54, 590-596. 
Dail DH, 1994. Eosinophilic infiltrates. In: Dail DH, Hammar SP. (Eds.) Pulmonary
Pathology, second ed, Springer, New York, USA, pp. 537-566. 
 57 57
Davidson JM. Biochemistry and turnover of lung interstitium. Eur Respir J
1990;3:1048-1063.
Davis WB, Fells GA, Sun XH, Gadek JE, Venet A, Crystal RG. Eosinophil-mediated
injury to lung parenchymal cells and interstitial matrix. A possible role for eosinophils 
in chronic inflammatory disorders of the lower respiratory tract. J Clin Invest 
1984;74:269-278.
Di Girolamo N, Wakefield D. In vitro and in vivo expression of interstitial 
collagenase/MMP-1 by human mast cells. Dev Immunol 2000;7:131-142. 
Ding Y, Uitto VJ, Haapasalo M, Lounatmaa K, Konttinen YT, Salo T, Grenier D,
Sorsa T. Membrane components of Treponema denticola trigger proteinase release 
from human polymorphonuclear leukocytes. J Dent Res 1996;75:1986-1993. 
Ding Y, Haapasalo M, Kerosuo E, Lounatmaa K, Kotiranta A, Sorsa T. Release and 
activation of human neutrophil matrix metallo- and serine proteinases during 
phagocytosis of Fusobacterium nucleatum, Porphyromonas gingivalis and Treponema
denticola. J Clin Periodontol 1997;24:237-248. 
Dryden, MW, Bolka, D,1992. Internal parasites. In Laboratory procedures for
veterinary technicians, P.W. Pratt (Ed). American Veterinary Publications inc,
California, USA, pp. 305-370. 
Dungworth DL, 1993. Lung In: Jubb K.V.F., Kennedy P.C., Palmer N. (Eds.) 
Pathology of domestic animals, fourth ed, Academic Press Inc., San Diego, USA, pp. 
571-608.
Ekblom M. Falk M, Salmivirta K, Durbeej M, Ekblom P. Laminin isoforms and 
epithelial development. Ann NY Acad Sci 1998;857:194-211.
Elkhal A, Tunggal L, Aumailley M.Fibroblasts contribute to the deposition of laminin
5 in the extracellular matrix. Exp Cell Res 2004;296:223-230.
Emingil G, Atilla G, Sorsa T, Luoto H, Kirilmaz L, Baylas H. The effect of adjunctive
low-dose doxycycline therapy on clinical parameters and gingival crevicular fluid 
matrix metalloproteinase-8 levels in chronic periodontitis. J Periodontol 2004a;75:106-
115.
Emingil G, Atilla G, Sorsa T, Savolainen P, Baylas H.Effectiveness of adjunctive low-
dose doxycycline therapy on clinical parameters and gingival crevicular fluid laminin-
5 gamma2 chain levels in chronic periodontitis. J Periodontol. 2004b;75:1387-1396. 
 58 58
Fosang AJ, Last K, Fujii Y, Seiki M, Okada Y. et al. Membrane-type 1 MMP (MMP-
14) cleaves at three sites in the aggrecan interglobular domain. FEBS Lett 
1998;430:186-190.
Fukuda Y, Basset F, Ferrans VJ, Yamanaka N. Significance of early intra-alveolar 
fibrotic lesions and integrin expression in lung biopsy specimens from patients with 
idiopathic pulmonary fibrosis. Hum Pathol 1995;26:53-61. 
Fukuda, Y, Ishizaki, M, Kudoh, S, Kitaichi, M, Yamanaka, N. Localization of matrix
metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in 
interstitial lung diseases. Laboratory Investigation 1998;78:687-698. 
Ghosh S, Stack MS. Proteolytic modification of laminins: functional consequences. 
Microsc Res Tech 2000;51: 238-246. 
Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. 
Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 
1997;277:225-228.
Gibbs, AR, Anderson, G, 1990. Pulmonary vasculitis and eosinophilic pneumonia. In:
R.A.L.Brewis, B. Corrin & D.M. Geddes (Eds.), Respiratory Medicine, WB Saunders
Co, London, UK, pp. 1165-1182.
Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL. Interaction of 92-kDa
type IV collagenase with the tissue inhibitor of metalloproteinases prevents
dimerization, complex formation with interstitial collagenase, and activation of the
proenzyme with stromelysin. J Biol Chem 1992;267:4583-4591. 
Golub LM, Lee HM, Greenwald RA, Ryan ME, Sorsa T, Salo T, Giannobile WV. A 
matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments
and specific collagenases in gingival crevicular fluid during adult periodontitis. 
Inflamm Res 1997;46:310-319. 
Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines 
inhibit connective tissue breakdown by multiple nonantimicrobial mechanisms. Adv 
Dent Res 1998;12:12-26. 
Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP.Tissue inhibitors of
metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 
1997;74:111-122.
 59 59
Grauer, GF, Riedesel, DH. Pulmonary infiltrates with eosinophilia. Iowa State 
University Veterinarian 1977;39, 92-97. 
Haley PJ, Muggenburg BA, Rebar AH, Shopp GM, Bice DE. Bronchoalveolar lavage 
cytology in cynomolgus monkeys and identification of cytologic alterations following 
sequential saline lavage. Vet Pathol 1989;26:265–273. 
Halliwell, REW, Gorman, NT, 1989. Hypersensitivity lung disease. In. REW Halliwell 
(Ed.) Veterinary Clinical Immunology, WB Saunders Co. Philadelphia, USA, pp. 369-
378.
Hanemaaijer R, Sorsa T, Konttinen YT, Ding Y, Sutinen M, Visser H, van Hinsbergh
VW, Helaakoski T, Kainulainen T, Ronka H, Tschesche H, Salo T. Matrix 
metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial 
cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem 
1997;272, 31504-31509. 
Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM. 
Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a 
model of herniated disc resorption. J Clin Invest 2000;105:143-150. 
Hawkins EC, Denicola DB, Kuehn NF. Bronchoalveolar lavage in the evaluation of 
pulmonary disease in the dog and cat: state of the art. J Vet Intern Med 1990;4:267–
274.
Hawkins EC, DeNicola DB, Plier ML. Cytological analysis of bronchoalveolar lavage 
fluid in the diagnosis of spontaneous respiratory tract disease in dogs: a retrospective 
study. J Vet Intern Med 1995;9:386-392. 
Hawkins EC, 1998. Disorders of pulmonary parenchyma. In:Nelson RW, Couto GC, 
(Eds.) Essential of small animal internal medicine. Mosby Inc., St Louis, USA, pp. 
299-314.
Hawkins EC, Berry CR. Use of a modified stomach tube for bronchoalveolar lavage in
dogs. J Am Vet Med Assoc 1999;215:1635-1639. 
Hayashi T, Stetler-Stevenson WG, Fleming MV, Fishback N, Koss MN, Liotta LA, 
Ferrans VJ, Travis WD. Immunohistochemical study of metalloproteinases and their 
tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic
pulmonary fibrosis. Am J Pathol 1996;149:1241-1256. 
Henry MT, McMahon K, Mackarel AJ, Prikk K, Sorsa T, Maisi P, Sepper R, 
Fitzgerald MX, O'Connor CM.  Matrix metalloproteinases and tissue inhibitor of 
metalloproteinase-1 in sarcoidosis and IPF. European Resp J 2002;20:1220-1227. 
 60 60
Hibbs MS, Mainardi CL, Kang AH. Type-specific collagen degradation by 
eosinophils. Biochem J 1982;207:621-624. 
Holopainen JM, Moilanen JA, Sorsa T, Kivelä-Rajamäki M, Tervahartiala T, 
Vesaluoma MH, Tervo TM. Activation of matrix metalloproteinase-8 by membrane
type 1-MMP and their expression in human tears after photorefractive keratectomy.
Invest Ophthalmol Vis Sci 2003;44:2550-2256. 
Hoshino, M, Takahashi, M, Takai, Y, Sim, J. Inhaled corticosteroids decrease 
subepithelial collagen deposition by modulation of the balance between matrix
metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J 
All Clin Imm 1999;104:356-363. 
Imai K, Dalal SS, Chen ES, Downey R, Schulman LL, Ginsburg M, D'Armiento J. 
Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients
with emphysema. Am J Respir Crit Care Med 2001;163:786-791. 
Inage M, Nakamura H, Kato S, Saito H, Abe S, Hino T, Tomoike H. Levels of 
cytokeratin 19 fragments in bronchoalveolar lavage fluid correlate to the intensity of
neutrophil and eosinophil-alveolitis in patients with idiopathic pulmonary fibrosis. 
Respir Med 2000;94:155-160. 
Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M, Matsuda H. Human mast cells 
produce matrix metalloproteinase 9. Eur J Immunol 1999;29:2645-2649. 
Kenagy RD, Clowes AW. A possible role for MMP-2 and MMP-9 in the migration of 
primate arterial smooth muscle cells through native matrix. Ann N Y Acad Sci 
1994;732:462-465.
Kiili M, Cox SW, Chen HY, Wahlgren J, Maisi P, Eley BM, Salo T, Sorsa
T.Collagenase-2 (MMP-8) and col lagenase-3 (MMP-13) in adult periodontitis: 
molecular forms and levels in gingival crevicular fluid and immunolocalisation in 
gingival tissue. J Clin Periodontol. 2002;29:224-232. 
King, LG, Hendricks, JC, 1995. Clinical pulmonary function tests. In: Ettinger SJ,
Feldman EC (Eds.), Textbook of veterinary internal medicine, WB Saunders Co., 
Philadelphia, USA, pp. 767-811.
Kivelä-Rajamäki M.J., Teronen O.P., Maisi P., Husa V., Tervahartiala T.I., Pirilä 
E.M., Salo T.A., Mellanen L., Sorsa T.A. Laminin-5 gamma2-chain and collagenase-2 
(MMP-8) in human peri-implant sulcular fluid. Clinical oral implants research
2003;14:158-165.
Klech H, Pohl W. Technical recommendations and guidelines for bronchoalveolar 
lavage (BAL). Reports of the S.E.P. Task Group on BAL. Eur Respir J 1989;2:561–
585.
 61 61
Knäuper V, Wilhelm SM, Seperack PK, DeClerck YA, Langley KE, Osthues A, 
Tschesche H. Direct activation of human neutrophil procollagenase by recombinant
stromelysin. Biochem J 1993;295:581-586. 
Knäuper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical
characterization of human collagenase-3. J Biol Chem 1996;271:1544-1550. 
Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, Kantor C, 
Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R. Tumor 
targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999;17:768-774. 
Konttinen YT, Halinen S, Hanemaaijer R, Sorsa T, Hietanen J, Ceponis A, Xu JW,
Manthorpe R, Whittington J, Larsson A, Salo T, Kjeldsen L, Stenman UH, Eisen AZ. 
Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the
pathogenesis of Sjögren's syndrome. Matrix Biol 1998;17:335-347. 
Koshikawa N, Moriyama K, Takamura H, Mizushima H, Nagashima Y, Yanoma S,
Miyazaki K Overexpression of laminin gamma2 chain monomer in invading gastric
carcinoma cells. Cancer Res 1999;59:5596-5601. 
Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface 
metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 
2000;148:615-624
Koshikawa N, Schenk S, Moeckel G, Sharabi A, Miyazaki K, Gardner H, Zent R, 
Quaranta V. Proteolytic processing of laminin-5 by MT1-MMP in tissues and its 
effects on epithelial cell morphology. FASEB J 2004;18:364-366.
Kumagai K, Ohno I, Okada S, Ohkawara Y, Suzuki K, Shinya T, Nagase H, Iwata K,
Shirato K. Inhibition of matrix metalloproteinases prevents allergen-induced airway
inflammation in a murine model of asthma. J Immunol 1999;162:4212-4219. 
Kähäri VM, Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol
1997;6:199-213.
Kähäri VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in 
tumour growth and invasion. Ann Med. 1999;31:34-45. 
Laitinen A, Laitinen LA. Airway morphology: epithelium/basement membrane. Am J 
Respir Crit Care Med 1994;150:14-17. 
Lambert E, Dasse E, Haye B, Petitfrere E. Lambert E, Dasse E, Haye B, Petitfrere E.
TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004;49:187-198.
 62 62
Lapointe JM, Vrins A, Lavoie JP. Effects of centrifugation and specimen preparation 
technique on bronchoalveolar lavage analysis in horses. Equine Vet J 1994;26:227-
229.
Lauhio A, Salo T, Ding Y, Konttinen YT, Nordström D, Tschesche H, Lähdevirta J,
Golub LM, Sorsa T. In vivo inhibition of human neutrophil collagenase (MMP-8)
activity during long-term combination therapy of doxycycline and nonsteroidal anti-
inflammatory drugs (NSAID) in acute reactive arthritis. Clin Exp Immunol
1994;98:21-28
Lee, W J, Shin, CY, Yoo, BK, Ryu, EY, Choi, JH, Cheong, JH, Ryu, Ko, KH. 
Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated
primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 
(Erk1/2). Glia 2003;41:15. 
Leeman MF, Curran S, Murray GI. Gelatinase B is involved in the in vitro wound 
repair of human respiratory epithelium. J Cell Physiol. 1996;66:413-426. 
Leeman MF, Curran S, Murray GI. The structure, regulation, and function of human
matrix metalloproteinase-13. Crit Rev Biochem Mol Biol 2002;37:149-166. 
Legrand C, Gilles C, Zahm JM, Polette M, Buisson AC, Kaplan H, Birembaut P, 
Tournier JM. Airway epithelial cell migration dynamics. MMP-9 role in cell-
extracellular matrix remodeling. J Cell Biol 1999;146:517-529. 
Lehti K, Lohi J, Valtanen H, Keski-Oja J. Proteolytic processing of membrane-type-1
matrix metalloproteinase is associated with gelatinase A activation at the cell surface. 
Biochem J 1998;334:345-353. 
Lemjabbar H, Gosset P, Lamblin C, Tillie I, Hartmann D, Wallaert B, Tonnel AB, 
Lafuma C. Contribution of 92 kDa gelatinase/type IV collagenase in bronchial
inflammation during status asthmaticus. Am J Resp Critical Care Med 1999;159:1298-
1307.
Leppert D, Hauser SL, Kishiyama JL, An S, Zeng L, Goetzl EJ. Stimulation of matrix
metalloproteinase-dependent migration of T cells by eicosanoids. FASEB J 
1995;9:1473-1481.
Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. Extracellular matrix
remodelling: the role of matrix metalloproteinases. J Pathol 2003;200:448-464. 
 63 63
 Levi E,  Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I. Matrix 
metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor 
receptor 1. Proc Natl Acad Sci USA. 1996;93:7069-7074.
Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, Lopez-Otin C. 
Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis
Rheum 1997;40:1391-1399. 
Lord, PF, Schaer, M, Tilley, L. Pulmonary infiltrates with eosinophilia in the dog. J
Am Vet Radiol Society 1975;16:115-20. 
Maisi P, Kiili M, Raulo SM, Pirila E, Sorsa T. MMP inhibition by chemically
modified tetracycline-3 (CMT-3) in equine pulmonary epithelial lining fluid. Ann N Y 
Acad Sci 1999;878:675-677. 
Maisi P, Prikk K, Sepper R, Pirila E, Salo T, Hietanen J, Sorsa T.Soluble membrane-
type 1 matrix metalloproteinase (MT1-MMP) and gelatinase A (MMP-2) in induced 
sputum and bronchoalveolar lavage fluid of human bronchial asthma and 
bronchiectasis. APMIS 2002;110:771-782. 
Mariani TJ, Sandefur S, Roby JD, Pierce RA. The structure, regulation, and function 
of human matrix metalloproteinase-13. Crit Rev Biochem Mol Biol 2002;37:149-166. 
Matsui C, Wang CK, Nelson CF, Bauer EA, Hoeffler WK. The assembly of laminin-5
subunits. J Biol Chem 1995;270:23496-23503. 
Matter H, Schudok M. Recent advances in the design of matrix metalloprotease
inhibitors. Curr Opin Drug Discov Devel 2004;7:513-535. 
Mayer P, Laber G, Walzl H. Bronchoalveolar lavage in dogs; analysis of proteins and 
respiratory cells. J Vet Med A 1990;37:392–399. 
McCauley M, Atwell RB, Sutton RH, Lumsden JS. Unguided bronchoalveolar lavage 
techniques and residual effects in dogs. Aust Vet J 1998;76:161-165. 
McMillan SJ, Kearley J, Campbell JD, Zhu XW, Larbi KY, Shipley JM, Senior RM, 
Nourshargh S, Lloyd CM. Matrix metalloproteinase-9 deficiency results in enhanced 
allergen-induced airway inflammation. J Immunol 2004;172:2586-2594. 
McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I, Overall 
CM. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-
derived factor-1. J Biol Chem 2001;276:43503-43508. 
Mellanen L, Salo T, Ingman T, Konttinen YT, Lahdevirta J, Sorsa T. 72-kDa and 92-
 64 64
kDa gelatinases in saliva of patients with human immunodeficiency virus infection. 
Acta Odontol Scand. 1998; 56:135-142. 
Michelson PH., Tigue M, Jones JC. Human bronchial epithelial cells secrete laminin 5, 
express hemidesmosomal proteins, and assemble hemidesmosomes. J Histochem 
Cytochem 2000;48:535-544.
Miyazaki K, Kikkawa Y, Nakamura A, Yasumitsu H, Umeda M. A large cell-adhesive
scatter factor secreted by human gastric carcinoma cells. Proc Natl Acad Sci U S A. 
1993;90:11767-11771.
Mizushima H, Koshikawa N, Moriyama K, Takamura H, Nagashima Y, Hirahara F, 
Miyazaki K. Wide distribution of laminin-5 gamma 2 chain in basement membranes of 
various human tissues. Horm Res 1998;50:7-14.
Moilanen M, Pirila E, Grenman R, Sorsa T, Salo T. Expression and regulation of 
collagenase-2 (MMP-8) in head and neck squamous cell carcinomas. J Pathol 
2002;197:72-81.
Moilanen M, Sorsa T, Stenman M, Nyberg P, Lindy O, Vesterinen J, Paju A, 
Konttinen YT, Stenman UH, Salo T. Tumor-associated trypsinogen-2 (trypsinogen-2)
activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades 
type I collagen. Biochem 2003;42:5414-5420. 
Mordelet-Dambrine M, Arnoux A, Stanislas-Leguern G, et al. Processing of lung 
lavage fluid causes variability in bronchoalveolar cell count. Am Rev Respir Dis
1984;130:305–306.
Muggenburg BA, Mauderly JL, Pickrell JA, Chiffelle TL, Jones RK, Luft UC, 
McClellan RO, Pfleger RC. Pathophysiologic sequelae of bronchopulmonary lavage in 
the dog. Am Rev Respir Dis 1972;106:219–232. 
Nagase H, Suzuki K, Enghild JJ, Salvesen G.Stepwise activation mechanisms of the 
precursors of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin).
Biomed Biochim Acta 1991;50:749-754. 
Noone, KE.1986. Pulmonary hypersensitivities. In: Kirk, RW (Ed.) Current Veterinary 
Therapy IX, WB Saunders Co, Philadelphia, USA, pp. 285-292.
Norris C, Mellema MS 2004. Eosinophilic pneumonia. In: King, LG (Ed.) Textbook of 
respiratory dsease in dogs and cats, WB Saunders Co, Philadelphia, USA, pp.541-547. 
Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ. Stromelysin is an 
activator of procollagenase. A study with natural and recombinant enzymes. Biochem 
J 1987;248:265-268. 
 65 65
Mäkelä M, Larjava H, Pirilä E, Maisi P, Salo T, Sorsa T, Uitto VJ. Matrix 
metalloproteinase 2 (gelatinase A) is related to migration of keratinocytes. Exp Cell 
Res 1999;251:67-78.
Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 
1997;378:151-160.
Nickel, R, Schummer, A, Seiferle, E, 1960. Lunge. In: Nickel, R., Schummer, A., 
Seiferle, E. (Eds.), Lehrbuch der anatomie der haustiere, band II. Paul Parey Verlag, 
Berlin, Germany, pp. 240-247. 
Noone, KE, (1986). Pulmonary hypersensitivities. In:Kirk, RW (Ed.) Current 
Veterinary Therapy IX, R.W. Kirk, WB Saunders Co Philadelphia, USA, pp. 285-292.  
O'Connor CM, FitzGerald MX. Matrix metalloproteases and lung disease. Thorax. 
1994;49:602-609.
Ohno, I, Ohtani, H, Nitta, Y, Suzuki, J, Hoshi, H, Honma, M, Isoyama, S, Tanno, Y, 
Tamura, G, Yamauchi, K, Nagura, H, Shirato, K. Eosinophils as a source of matrix
metalloproteinase-9 in asthmatic airway inflammation. Am J Resp Cell Mol Biol
1987;16: 212-219. 
Ogawa T, Tsubota Y, Maeda M, Kariya Y, Miyazaki K. Regulation of biological 
activity of laminin-5 by proteolytic processing of gamma2 chain. J Cell Biochem. 
2004;92:701-714.
Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 
2002;3:409-421.
Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT. Matrix 
metalloproteinase-mediated extracellular matrix protein degradation in human
pulmonary emphysema. Lab Invest 1998;78:1077-1087. 
Okada S, Kita H, George TJ, Gleich GJ, Leiferman KM. Migration of eosinophils 
through basement membrane components in vitro: role of matrix metalloproteinase-9.
Am J Respir Cell Mol Biol 1997;17:519-528. 
Owen CA, Hu Z, Lopez-Otin C, Shapiro SD. Membrane-bound matrix
metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor 
of metalloproteinase-resistant collagenase and serpinase. J Immunol 2004;172:7791-
7803.
Palosaari H, Wahlgren J, Larmas M, Ronka H, Sorsa T, Salo T, Tjaderhane L. 
Collagenase-3 induction in rat lung fibroblasts requires the combined effects of tumor 
necrosis factor-alpha and 12-lipoxygenase metabolites: a model of macrophage-
induced, fibroblast-driven extracellular matrix remodeling during inflammatory lung 
injury. Mol Biol Cell. 1998;9:1411-1424. 
66
Palosaari H, Wahlgren J, Larmas M, Ronka H, Sorsa T, Salo T, Tjäderhane L. The
expression of MMP-8 in human odontoblasts and dental pulp cells is down-regulated 
by TGF-beta1. J Dent Res 2000;79:77-84. 
Pardo A, Barrios R, Maldonado V, Melendez J, Perez J, Ruiz V, Segura-Valdez L, 
Sznajder JI, Selman M. Gelatinases A and B are up-regulated in rat lungs by subacute 
hyperoxia: pathogenetic implications. Am J Pathol 1998;153:833-844. 
Park HS, Kim HA, Jung JW, Kim YK, Lee SK, Kim SS, Nahm TH. T cell gelatinases 
mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-4389. 
Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res 
2001;2:10-19.
Peeters DE, McKiernan BC, Weisiger RM, Schaeffer DJ, Clercx C. Quantitative 
bacterial cultures and cytological examination of bronchoalveolar lavage specimens in 
dogs. J Vet Intern Med 2000;14:534-541. 
Perez-Arellano JL, Pedraz MJ, Fuertes A, de la Cruz JL, Gonzalez de Buitrago JM, 
Jimenez A. Laminin fragment P1 is increased in the lower respiratory tract of patients
with diffuse interstitial lung diseases. Chest 1993;104,1163-1169. 
Perez-Ramos J, de Lourdes Segura-Valdez M, Vanda B, Selman M, Pardo A. Matrix 
metalloproteinases 2, 9, and 13, and tissue inhibitors of metalloproteinases 1 and 2 in 
experimental lung silicosis. Am J Respir Crit Care Med 1999;160:1274-1282. 
Pirilä E, Sharabi A, Salo T, Quaranta V, Tu H, Heljasvaara R, Koshikawa N, Sorsa T, 
Maisi P. Matrix metalloproteinases process the laminin-5 gamma 2-chain and regulate 
epithelial cell migration. Biochem Biophys Res Commun 2003;303:1012-1017. 
Pinsker KL, Norin AJ, Kamholz SL, Montefusco C, Schreiber K, Hagstrom JW, Veith 
FJ. Cell content in repetitive canine bronchoalveolar lavage. Acta Cytol 1980;24:558–
563.
Plopper G, Falk-Marzillier J, Glaser S, Fitchmun M, Giannelli G, Romano T, Jones 
JC, Quaranta V. Changes in expression of monoclonal antibody epitopes on laminin-5r
induced by cell contact. J Cell Sci. 1996;109:1965-1973. 
Prikk K, Maisi P, Sepper R, Stenman UH, Salo T, Sorsa T. Association of trypsin-2
with activation of gelatinase B and collagenase-2 in human bronchoalveolar lavage 
fluid in vivo. Ann Med 2001a;33:437-444.
 67 67
Prikk K, Maisi P, Pirilä E, Sepper R, Salo T, Wahlgren J, Sorsa T. In vivo 
collagenase-2 (MMP-8) expression by human bronchial epithelial cells and
monocytes/macrophages in bronchiectasis. Journal Pathol 2001a;194: 232-238. 
Prikk K, Maisi P, Pirila E, Reintam MA, Salo T, Sorsa T, Sepper R. Airway
obstruction correlates with collagenase-2 (MMP-8) expression and activation in 
bronchial asthma. Lab Invest. 2002;82:1535-1545. 
Pyke C, Romer J, Kallunki P, Lund LR, Ralfkiaer E, Dano K, Tryggvason K. The
gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant
cells in human cancers. Am J Pathol 1994;145:782-791. 
Ramnath N, Creaven PJ. Matrix metalloproteinase inhibitors. Curr Oncol Rep 
2004;6:96-102.
Rebar AH, DeNicola DB, Muggenburg BA. Bronchopulmonary lavage cytology in the 
dog: normal findings. Vet Pathol 1980;17:294–304. 
Rennard SI, Aalbers R, Bleecker E, Klech H, Rosenwasser L, Olivieri D, Sibille Y. 
Bronchoalveolar lavage: performance, sampling procedure, processing and 
assessment. Eur Respir J Suppl 1998;26:13S–15S. 
Raulo SM, Maisi P. Gelatinolytic activity in tracheal epithelial lining fluid and in 
blood from horses with chronic obstructive pulmonary disease. Am J Vet Res. 
1998;59:818-823.
Raulo SM, Sorsa TA, Kiili MT, Maisi PS. Evaluation of collagenase activity, matrix
metalloproteinase-8, and matrix metalloproteinase-13 in horses with chronic 
obstructive pulmonary disease. Am J Vet Res 2001a;62:1142-1148. 
Raulo SM, Sorsa TA, Tervahartiala T, Pirilä E, Maisi P. MMP-9 as a marker of 
inflammation in tracheal epithelial lining fluid (TELF) and in bronchoalveolar fluid
(BALF) of COPD horses. Eq Vet J 2001b;33, 128-136. 
Rebar AH, DeNicola DB, Muggenburg BA. Bronchopulmonary lavage cytology in the 
dog: normal findings. Vet Pathol 1980;17:294–304. 
Robinson NE, Gillespie JR. Morphologic features of the lungs of aging beagle dogs.
Am Rev Respir Dis 1973;108:1192–1199. 
Romanelli R, Mancini S, Laschinger C, et al. Activation of neutrophil collagenase in 
periodontitis. Infect Immun 1999;67:2319-2326. 
 68 68
Saari H, Suomalainen K, Lindy O, Konttinen YT, Sorsa T. Activation of latent human
neutrophil collagenase by reactive oxygen species and serine proteases. Biochem
Biophys Res Commun 1990;171:979-987 
Saltini C, Hance AJ, Ferrans VJ, Basset F, Bitterman PB, Crystal RG. Accurate 
quantification of cells recovered by bronchoalveolar lavage. Am Rev Respir Dis 
1984;130:650–658.
Sannes PL, Wang J. Basement membranes and pulmonary development. Exp Lung 
Res 1997;23, 101-108.
Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN, 
Bird RE, Hoythya M, Fuerst TR, French DL, et al. Type IV collagenase(s) and TIMPs
modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993;156:235-246. 
Schwarz M, 1998. Approach to understanding, diagnosis, and management of
interstitial disease In: Schwarz M., King T. (Eds.) Interstitial lung disease, third ed., 
BC Decker Inc, Hamilton, Ontario, Canada, pp. 3-30. 
Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M. Upregulation 
of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in 
COPD. Chest 2000;117:684-694.
Sepper R, Konttinen YT, Sorsa T, Koski H. Gelatinolytic and type IV collagenolytic
activity in bronchiectasis. Chest 1994;106:1129-1133. 
Sepper R, Konttinen YT, Ding Y, Takagi M, Sorsa T. Human neutrophil collagenase
(MMP-8), identified in bronchiectasis BAL fluid, correlates with severity of disease. 
Chest 1995;107:1641-1647. 
Shan L, Nishimura Y, Kotani Y, Yokoyama M. MMP-2- and MMP-9-linked 
gelatinolytic activity in the sputum from patients with asthma and chronic obstructive 
pulmonary disease. Int Arch Allergy Immunol 2000;123:259-267. 
Shapiro SD, Campbell EJ, Kobayashi DK, Welgus HG. Dexamethasone selectively 
modulate basal and lipopolysaccharide induced metalloproteinase and tissue inhibitor
of metalloproteinase production by human alveolar macrophages. J Immunol
1991;146:2724-2729.
Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological
consequences. Curr Opin Cell Biol 1998;10:602-608. 
Shapiro SD, Senior RM. Matrix metalloproteinases. Matrix degradation and more. Am 
J Respir Cell Mol Biol 1999;20:1100-1102. 
 69 69
Shute JK, Parmar J, Holgate ST, Howart PH. Urinary glycosaminoglycan levels are 
increased in acute severe asthma-a role for eosinophil-derived gelatinase B? Int Arch 
Allergy Immunol 1997;113:366-367. 
Silverstein D, Greene C, Gregory C, Lucas S, Quandt J. Pulmonary alveolar 
proteinosis in a dog. J Vet Intern Med 2000t;14:546-551. 
Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu 
Rev Cell Dev Biol 2001;17:463-516. 
Suga M, Iyonaga K, Okamoto T, Gushima Y, Miyakawa H, Akaike T, Ando M. 
Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial
pneumonias. Am J Respir Crit Care Med 2000;162:1949-1956. 
Suter, PF, 1984. Lower airway and pulmonary parenchymal diseases. In: Suter PF,
Lord PF (Eds.). Thoracic radiography. A text atlas of thoracic diseases of the dog and 
cat, Peter F. Suter, author’s edition, Wettswil, Switzerland, pp. 570-75.
Sorsa T, Saari, H., Konttinen, YT, Uitto VJ, Lindy S. Tissue destrtuction by
neutrophils. A research letter. N Engl Med 1989: 321, 327-328. 
Sorsa T, Ingman T, Suomalainen K, Haapasalo M, Konttinen YT, Lindy O, Saari H, 
Uitto VJ. Identification of proteases from periodontopathogenic bacteria as activators
of latent human neutrophil and fibroblast-type interstitial collagenases. Infect Immun.
1992;60:4491-4495.
Sorsa T, Ding Y, Salo T Lauhio A, Teronen O, Ingman T, Ohtani H, Andoh N, Takeha
S, Konttinen YT. Effects of tetracyclines on neutrophil, gingival, and salivary
collagenases. A functional and western-blot assessment with special reference to their
cellular sources in periodontal diseases. Ann N Y Acad Sci 1994;732:112-131. 
Sorsa T, Salo T, Koivunen E, Tyynela J, Konttinen YT, Bergmann U, Tuuttila A, 
Niemi E, Teronen O, Heikkila P, Tschesche H, Leinonen J, Osman S, Stenman UH. 
Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol 
Chem. 1997;272:21067-21074.
Sorsa T, Tjäderhane L, Salo T. Maytrix metalloproteinases (MMPs) in oral diseases. 
Oral Dis 2004;10:311-318. 
Stamenkovic I. Induction of cell migration by matrix metalloprotease-2 cleavage of 
laminin-5. Science 1997;277:225-228. 
Suzuki R, Miyazaki Y, Takagi K, Torii K, Taniguchi H. Matrix metalloproteinases in
the pathogenesis of asthma and COPD: implications for therapy. Treat Respir Med 
2004;3:17-27.
 70 70
Sweeney CR, Rossier Y, Ziemer EL, Lindborg SR. Effect of prior lavage on 
bronchoalveolar lavage fluid cell population of lavaged and unlavaged lung segments
in horses. Am J Vet Res 1994;55:1501–1504. 
Taboada, J. Pulmonary diseases of potential allergic origin. Semin Vet Med Surg
(Small Anim). 1991;6: 278-285.
Torii K, Iida K, Miyazaki Y, Saga S, Kondoh Y, Taniguchi H, Taki F, Takagi K, 
Matsuyama M, Suzuki R. Higher concentrations of matrix metalloproteinases in 
bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome.
American journal of respiratory and critical care medicine 1997;155: 43-46. 
Triebel S, Blaser J, Reinke H, Tschesche H. A 25 kDa alpha 2-microglobulin-related
protein is a component of the 125 kDa form of human gelatinase. FEBS Lett.
1992;314:386-388.
Tschesche H, Knauper V, Kramer S, Michaelis J, Oberhoff R, Reinke H.Latent 
collagenase and gelatinase from human neutrophils and their activation. Matrix Suppl
1992;1:245-255.
Vail DM, Mahler PA, Soergel SA. Differential cell analysis and phenotypic subtyping 
of lymphocytes in bronchoalveolar lavage fluid from clinically normal dogs. Am J Vet
Res 1995;56:282–285. 
Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of 
metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827-839. 
Wahlgren J, Maisi P, Sorsa T, Sutinen M, Tervahartiala T, Pirila E, Teronen O,
Hietanen J, Tjaderhane L, Salo T. Expression and induction of collagenases (MMP-8 
and -13) in plasma cells associated with bone-destructive lesions. J Pathol 
2001;194:217-224.
Wahlgren J, Väänänen A, Teronen O, Sorsa T, Pirilä E, Hietanen J, Maisi P, 
Tjäderhane L, Salo T, 2003. Laminin-5 gamma 2 chain is colocalized with gelatinase-
A (MMP-2) and collagenase-3 (MMP-13) in odontogenic keratocysts. J Oral Path Med 
2003;32:100-107.
Wang Z, Juttermann R, Soloway PD. TIMP-2 is required for efficient activation of 
proMMP-2 in vivo. J Biol Chem 2000;275:26411-26415. 
Ward C, Effros RM, Walters EH. Assessment of epithelial lining fluid dilution during
bronchoalveolar lavage. Eur Respir rev 1999;9:32-37. 
 71 71
Warner RL, Bhagavathula N, Nerusu KC, Lateef H, Younkin E, Johnson KJ, Varani J. 
Matrix metalloproteinases in acute inflammation: induction of MMP-3 and MMP-9 in 
fibroblasts and epithelial cells following exposure to pro-inflammatory mediators in 
vitro. Exp Mol Pathol 2004;76:189-195. 
Westerlund U, Ingman T, Lukinmaa PL, Salo T, Kjeldsen L, Borregaard N, 
Tjaderhane L, Konttinen YT, Sorsa T. Human neutrophil gelatinase and associated
lipocalin in adult and localized juvenile periodontitis. J Dent Res 1996;75:1553-1563. 
Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI. SV40-
transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is 
identical to that secreted by normal human macrophages. J Biol Chem
1989;264:17213-17221.
Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, Stratman JL, 
Hultgren SJ, Matrisian LM, Parks WC. Regulation of intestinal alpha-defensin
activation by the metalloproteinase matrilysin in innate host defense. Science
1999;286:113-117.
Wingfield, WE, Matteson, VL, Hackett, T, Walton, R, Lagutchik, M. Arterial blood 
gases in dogs with bacterial pneumonia. J Vet Em Crit Care 1997;7:75-8. 
Woo CH, Lim JH, Kim JH. Lipopolysaccharide induces matrix metalloproteinase-9
expression via a mitochondrial reactive oxygen species-p38 kinase-activator protein-1 
pathway in Raw 264.7 cells. J Immunol 2004;173:6973-6980. 
Woodside KH, Latham SB, Denas SM. Increased recovery of neutrophils, 
macrophages and lymphocytes following repeated lavage of sheep lung in vivo. Exp 
Lung Res 1983;5:295–303. 
Tervahartiala T, Pirila E, Ceponis A, Maisi P, Salo T, Tuter G, Kallio P, Tornwall J,
Srinivas R, Konttinen YT, Sorsa T.The in vivo expression of the collagenolytic matrix
metalloproteinases (MMP-2, -8, -13, and -14) and matrilysin (MMP-7) in adult and 
localized juvenile periodontitis. Dent Res 2000;79:1969-1977. 
Yao PM, Lemjabbar H, D'Ortho MP, Maitre B, Gossett P, Wallaert B, Lafuma C. 
Balance between MMP-9 and TIMP-1 expressed by human bronchial epithelial cells: 
relevance to asthma. Ann N Y Acad Sci 1999;878:512-514. 
 Yokota H, Kumata T, Taketaba S, Kobayashi T, Moue H, Taniyama H, Hirayama K, 
Kagawa Y, Itoh N, Fujita O, Nakade T, Yuasa A. High expression of 92 kDa type IV 
collagenase (matrix metalloproteinase-9) in canine mammary adenocarcinoma.
Biochim Biophys Acta 2001;1568:7-12. 
 72 72
Yurchenco PD, O'Rear JJ. Basement membrane assembly. Methods Enzymol 
1994;245: 489-518.
Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L, Morris D,
Kim Y, DeLustro B, Sheppard D, Pardo A, Selman M, Heller RA. Gene expression 
analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and 
humans. Proc Natl Acad Sci USA 2002;99:6292-6297. 
 73 73
